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ABSTRACT 
Tishan L. Williams: Mechanism-based Inhibition of Bacterial and Mitochondrial Tryptophanyl-
tRNA Synthesases is Potentiated by Mg2+•ATP 
(Under the direction of Charles W. Carter, Jr.) 
 
Eukaryotes have distinct nuclear genes for tryptophanyl-tRNA synthetase (TrpRS) 
enzymes targeted by N-terminal sequence variations to the cytoplasm (Hc) and mitochondria 
(Hmt) that share only 14% sequence identity. Indolmycin, a natural tryptophan analog, competes 
with tryptophan for binding to tryptophanyl-tRNA synthetase (TrpRS) enzymes. Although 
bacterial and eukaryotic cytosolic TrpRSs have comparable affinities for tryptophan, KM ~2 µM, 
eukaryotic cytosolic TrpRS enzymes are able to evade inhibition by indolmycin. Tryptophan 
binding to Bacillus stearothermophilus (Bs) TrpRS is largely promoted by hydrophobic 
interactions and recognition of the indole nitrogen by the side chain of Asp 132. By contrast, 
HcTrpRS complements non polar interactions for tryptophan binding with electrostatic and 
hydrogen bonding interactions, which we show by modelling are inconsistent with indolmycin 
binding. Our crystallographic and inhibition kinetics data show the non-reactive analog 
indolmycin can recruit unique polar interactions to form an active-site metal coordination that 
lies off the normal mechanistic path, enhancing affinity to BsTrpRS and other prokaryotic TrpRS 
enzymes by 1500-fold over its tryptophan substrate. The Mg2+ ion in the inhibited complex forms 
significantly closer contacts with triphosphate oxygen atoms of ATP and three water molecules 
than occur in the catalytically-competent pre-transition state (preTS). Indolmycin binding also 
leads to weakened interactions between ATP and active-site lysine side-chains. Confirmation of 
our interpretation of structural consequences of indolmycin binding comes from a 1.82 Å crystal 
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structure of an indolmycin-inhibited HmtTrpRS complex. This structure unequivocally 
demonstrates the use of similar determinants by mitochondrial and bacterial TrpRS enzymes to 
bind both ATP and indolmycin, with the mitochondrial enzyme forming similar ATP-enzyme, 
ATP-metal and indolmycin-enzyme interactions. Indolmycin binds HmtTrpRS ~700-times tighter 
than tryptophan and Mg2+•ATP leads to an ~80-fold enhancement in indolmycin binding affinity. 
The oxazolinone- Mg2+•ATP interaction contributes ~-2.2 kcal/mol to the Gibbs free energy of 
the fully-liganded indolmycin inhibited HmtTrpRS complex. Together, our complementary 
structural, kinetic and thermodynamic characterization of BsTrpRS and HmtTrpRS establish a 
shared mechanism for indolmycin inhibition of mitochondrial and prokaryotic TrpRS enzymes, 
which bind indolmycin 105-106-fold tighter than eukaryotic cytosolic homologs. 
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CHAPTER I: INTRODUCTION 
 
The never-ending cycle of drug development and antibiotic resistance 
 
Antibiotic selective pressure ensures that only microbes that have either acquired or 
evolved methods by which to evade drug action will survive and propagate. Adaptive responses 
by pathogenic bacteria over time and following prolonged use of anti-infectives to treat infected 
individuals allow bacteria to develop resistance. Despite the great variety among bacterial 
species and antibiotics, resistance emerges primarily via three well-characterized mechanisms; i) 
enzyme-catalyzed inactivation of antibiotic (1-3),  ii) reduced affinity for antibiotic by 
reprogramming of drug target structure (4, 5), and iii) reduced intracellular drug concentration 
due to increased efflux or decreased cellular import (6-8). The accumulation of resistance 
through genomic alterations in pathogenic organisms necessitates the perpetual development of 
new anti-infective therapeutics. A common method employed to increase the available arsenal of 
antibiotics is to chemically modify existing compounds that bind to exploited targets but can, due 
to the modification, counteract current resistance mechanisms.  
One over-utilized target for anti-infective action is the ribosome (Table 1). Drugs 
targeting the ribosome have been around since the beginning of the antibiotic era with the latest 
drug class targeting the 50S ribosomal subunit becoming clinically-relevant in 2000. The 
emergence of resistance in response to compounds from each class belies the need for new 
compounds targeting other essential translation components (9). Divergent evolution between 
proteins involved in prokaryotic and eukaryotic translation yields a number of attractive targets 
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for selective inhibition of prokaryotic translation (10-13). One validated but under-exploited 
class of targets is the aminoacyl-tRNA synthetase family (14). 
Drug Class Year of Clinical Introduction Target 
Aminoglycosides 1946 30S ribosomal subunit 
Phenicols 1948 50S ribosomal subunit 
Macrolides 1951 50S ribosomal subunit 
Tetracyclines 1952 30S ribosomal subunit 
Streptogramins 1999 50S ribosomal subunit 
Oxazolidinones 2000 50S ribosomal subunit 
Table 1: Antibiotics targeting the translation pathway. Many antibiotics make use of divergent 
elements involved in prokaryotic and eukaryotic translation for selective inhibition of the prokaryotic 
pathway. The 30S and 50S ribosomal subunits are the targets of multiple drug classes. 
aaRS as antibiotic targets  
 
Protein synthesis is essential for life and fidelity of the genetic code depends on the specific 
pairing of tRNA with cognate amino acid by the suite of aminoacyl-tRNA synthetases (aaRS). 
Organisms in all kingdoms of life utilize aaRS enzymes to catalyze the following two-step 
tRNA-charging reaction:  
1. Amino acid activation: aaRS + ATP + aa ⇄ aaRS•aa-AMP + PPi 
2. Aminoacyl transfer: aaRS•aa-AMP + tRNA ⇄ aaRS + aa-tRNA + AMP 
In the first step, aaRS binds both ATP and the amino acid (aa) for which it is selective such that 
the nucleophilic carboxylate of the amino acid can attack the ATP α-phosphate. Pyrophosphate 
(PPi) is released in the process and the enzyme retains an aminoacyl-adenylate (aa-AMP) 
intermediate to be used as a substrate for the second step. Aminoacyl transfer occurs when either 
the 2’ or 3’ hydroxyl of the terminal tRNA adenosine attacks the α-carbonyl of aa-AMP. An 
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ester bond links the amino acid to the 3’ adenosine of tRNA (aa-tRNA) and AMP is released. 
While all aaRS bind ATP, they utilize distinct structural and sequence motifs that allow for their 
grouping into one of two classes. Class I synthetases employ HIGH and KMSKS signature 
sequences contained within a characteristic Rossmann fold to bind ATP in an extended 
configuration. TRNA-charging by members of this class occurs exclusively via the 2’hydroxyl. 
Class II aaRS have three signature sequences, Motifs 1-3, and bind a bent ATP conformer at an 
active site that consists of anti-parallel β-sheets (15, 16).  
 It is evident that targeted inhibition of aaRS enzymes can be achieved by blocking either 
step of the two-step charging reaction. Amino acid activation of all aaRSs should be inhibited by 
non-reactive ATP analogues whereas individual aaRS can be targeted by amino acid analogues 
as is the case for TrpRS inhibition by indolmycin (17-19). Similarly, structural analogues of the 
aminoacyl-adenylate intermediate are potent aaRS inhibitors. Mupirocin, used in the treatment of 
methicillin-resistant Staphylococcus aureus (MRSA) infections, inhibits Isoleucyl-tRNA 
synthetase (IleRS) by blocking the isoleucyl-adenylate (Ile-AMP) binding site (10). Sequence 
variation among prokaryotic and eukaryotic IleRS homologs in active-site residues allows for 
selective inhibition of bacterial over eukaryotic IleRS by mupirocin (10). Mupirocin validates the 
aaRS enzyme family as a druggable target for antibiotic development and demonstrates the 
pivotal role of structural and sequence differences between eukaryotic and prokaryotic aaRS in 
achieving selective inhibition of prokaryotic synthetases by novel anti-infective therapeutics. 
Prokaryotic versus eukaryotic TrpRS 
 
Differential structural responses to ligand binding 
Extensive structural and kinetic characterization of tryptophanyl-tRNA synthetases from 
prokaryotic and eukaryotic organisms has uncovered conserved and divergent features utilized in 
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the catalysis of tryptophan activation (17, 20-25). Comparison of primary TrpRS sequences 
identified N-terminal eukaryote-specific (ESE) and vertebrate-specific extensions (VSE) that are 
absent from all bacterial TrpRS enzymes (25). Furthermore, two lysine residues (Lys 111 and 
Lys 195) and an aspartic acid (Asp 132) shown to interact with the PPi leaving group of ATP and 
NE1 atom of tryptophan by Bacillus stearothermophilus (Bs)TrpRS, respectively, are missing 
from eukaryotic TrpRS. Together, these sequence variations point to the use of non-conserved 
active-site residues in the recognition and binding of both substrates by eukaryotic TrpRS.  
 The structural changes accompanying tryptophan activation (Trp + ATP → TYM + PPi) 
by BsTrpRS are well-characterized (Fig. 1A). In the absence of ligands (1D2R), the enzyme 
exists in an open conformation (26). This same open state is observed when either ATP (1MAW) 
or tryptophan (1MB2) separately occupies the active site (22). Induced-fit closing of the active 
site to form the pre-transition state (preTS) results from full-ligation with ATP and tryptophan 
(1MAU; (22)). The transition from open to closed is facilitated by movements of the mobile loop 
containing Lys 111 (~3 Å), the specificity helix (~3 Å), GxDQ (~1.5 Å), HIGH (~3 Å) and the 
KMSKS loop (~4 Å). At high concentrations ATP can drive closing of the active site to form the 
pre-transition state (1M83).  
In contrast, human cytosolic (Hc) TrpRS, which does not engage residues in the 
specificity helix for tryptophan recognition, adopts a closed state in response to tryptophan 
binding (2QUH; (23)). The apo (1O5T; (27)) and tryptophan-bound HcTrpRS complexes differ 
by 0.8 Å (316 Cα pairs) compared to the 0.3 Å RMSD (301 Cα pairs) for the corresponding 
BsTrpRS structures (Fig. 1B). Structural changes accompanying tryptophan binding include 
movements toward the active site by the KMSAS loop (0.8 Å), GxDQ (~2 Å) and the loop containing Arg 
162 (~1.2 Å). Superposition of the tryptophan- and tryptophanamide+ATP-bound (2QUI; (23)) HcTrpRS 
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Figure 1: Varied structural consequences of substrate binding to prokaryotic and eukaryotic 
TrpRS. (A) BsTrpRS resides in an open state conformation in the absence of ligands (black) and 
transitions to a closed, preTS conformation when both ATP and tryptophan(amide) are bound (pink). 
Tryptophan activation is accompanied by a slight opening of the KMSKS loop (yellow). (B) Smaller 
global movements occur when HcTrpRS goes from open (apo; black) to closed, preTS (pink) to closed, 
product (yellow) conformation. Tryptophan-bound BsTrpRS favors the open apo-BsTrpRS structure 
whereas tryptophan-HcTrpRS favors the closed, preTS HcTrpRS complex. 
A 
B 
 6 
 
 
 
complexes showed a high degree of structural similarity with an RMSD of 0.3 Å for 298 Cα 
pairs. The addition of ATP in the HcTrpRS preTS complex closes the KMSAS loop by an 
additional 2 Å. Overall, less dramatic structural changes accompany the transition from open, 
ligand-free state to closed, pre-transition state by HcTrpRS (0.7 Å) than BsTrpRS (2.5 Å).   
Tryptophan recognition 
 Tryptophan binds in a hydrophobic pocket within the BsTrpRS active site (Fig. 2A). 
BsTrpRS utilizes the carboxylate side-chain of Asp 132 to recognize the indole nitrogen of 
substrate tryptophan. Other stabilizing interactions include hydrophobic van der Waals (Ile 8, 
Val 40, Val 141, Val 143, Ile 133, and Ile 151), π-π (Phe 5) and π-sulfur (Met 129) interactions. 
In contrast, HcTrpRS relies more heavily on hydrogen bonding interactions with Tyr 159 and Gln 
194 for tryptophan recognition (Fig. 2B). Additional direct polar interactions with four active-
site side-chains (Glu 199, Lys 200, Gln 284 and Gln 313) and π-π (Phe 317 and Tyr 159) 
interactions promote tryptophan binding to HcTrpRS. 
Bent versus extended ATP configuration 
 HcTrpRS and BsTrpRS bind different ATP conformers, with BsTrpRS binding the 
extended conformer that is characteristic for Class I aminoacyl-tRNA synthetases. BsTrpRS 
engages three active-site lysine residues to stabilize the triphosphate group of ATP. Two of these 
lysines (192 and 111) compete with the catalytic Mg2+ ion electrostatically coupled to each 
phosphate group for negatively charged oxygen atoms in the eventual PPi leaving group. Lysine 
195 forms a salt bridge with an α-phosphate oxygen atom. While Lys 192 is conserved in all 
TrpRS enzymes, Lys 111 and Lys 195 are missing from eukaryotic cytosolic TrpRSs. Instead, 
HcTrpRS uses Lys 349 (KMSAS; Lys 195BS) to stabilize an α-phosphate oxygen atom, while Ser 
351, Ser 353 and Ser 165 form hydrogen bonding interactions with β-phosphate oxygen atoms. 
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Figure 2: Differential modes of tryptophan recognition. (A) Prokaryotic TrpRS enzymes use a strictly 
conserved aspartic acid to recognize the NE1 atom of tryptophan. (B) The tryptophan binding pocket of 
eukaryotic cytosolic TrpRS is more polar and less hydrophobic than that of prokaryotic homologs. 
 
The γ-phosphate group interacts with Arg 162 and His 173 (HIGH) side-chains. Arg 162 is close 
in sequence to the eukaryotic-specific extension (ESE) which Yang et al. showed was involved 
in ATP binding (25). Deletion of the ESE reduces ATP binding ~25-fold.  
Pre-transition states and Mg2+ coordination 
From Figure 1 it is clear that BsTrpRS-bound ATP and tryptophan need minimal 
movements for nucleophilic attack of the α-phosphate by the tryptophan carboxylate; i.e. the 
indole and AMP moieties occupy similar positions in the pre-transition state and product state 
structures. Induced-fit closing of the active site in response to ATP binding is responsible for the 
proper placement of the ATP for catalysis to proceed. Contrastingly, the preTS complex for 
HcTrpRS, which closes in response to tryptophan instead of ATP binding, shows the ATP α-
phosphate must move closer to tryptophan by ~5 Å before catalysis can occur. Interestingly, 
ATP movement is not facilitated by HcTrpRS structural changes.  
B A 
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In addition to differences in ATP conformation and ATP-enzyme interactions, 
comparison of the bacterial and eukaryotic pre-transition state complexes reveals a distinct 
difference in Mg2+ ion placement and coordination. In HcTrpRS, the metal lies between the α- 
and β-phosphate groups. The bent ATP configuration places the γ-phosphate group too far away 
for electrostatic coupling of this group with Mg2+. The coordination sphere for the Mg2+ ion 
consists of oxygen atoms from the α- and β-phosphate groups, the side-chain hydroxyl group of 
Ser 165 and a stable water molecule. The precise role of Mg2+ in assisting tryptophan activation 
by HcTrpRS and other eukaryotic TrpRS enzymes remains undefined. 
 Contrastingly, BsTrpRS does not form any direct interactions with Mg2+ and the metal 
forms electrostatic interactions with an oxygen atom from each phosphate group of ATP and one 
stable water molecule. As will be discussed in Chapter II the placement and coordination of the 
Mg2+ ion within the BsTrpRS active site is dependent on ATP and the identity of the ligand 
occupying the tryptophan binding pocket. BsTrpRS couples the metal to an allosteric center 
remote from the active site called the D1 switch (20, 21). Side-chain rearrangements between 
residues of the D1 switch are responsible for activating the catalytic metal. Activation involves 
movement of Mg2+ toward the eventual PPi leaving group, allowing for stabilization of the 
negative charge during the catalytic transition to tryptophanyl-5’AMP formation.  
Indolmycin Inhibition 
 
Varied modes of substrate binding, utilization of non-conserved residues in substrate 
recognition, and differential catalytic assist by Mg2+ all point toward tryptophan activation 
proceeding via different mechanisms for bacterial and eukaryotic cytosolic TrpRS enzymes. 
These differences can be exploited to selectively inhibit prokaryotic TrpRS with small molecule 
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inhibitors, thereby making TrpRS a suitable target for novel anti-infective therapies to treat 
infected individuals. The relatively minor structural differences between tryptophan and 
indolmycin (Fig. 3), a  naturally-occurring prokaryotic-specific TrpRS inhibitor produced by 
Streptomyces griseus, allow for comparable tryptophan affinities but drastically different 
indolmycin affinities between prokaryotic and eukaryotic cytosolic TrpRS homologs (19). 
Binding of indolmycin to prokaryotic and eukaryotic cytosolic TrpRS enzymes differs by six 
orders of magnitude (18, 19).  
In addition to cytosolic TrpRS, eukaryotes express a second TrpRS required for 
translation of the mitochondrial genome. Mitochondrial TrpRS is nuclear-encoded and translated 
in the cytosol prior to mitochondrial import (28). Any potential clinically-useful TrpRS 
inhibitors need to avoid inhibition of both cytosolic and mitochondrial TrpRS to prevent 
deleterious side-effects. Lack of structural information about mitochondrial TrpRS has hindered 
our understanding of the binding determinants used for substrate recognition by these enzymes. 
Sequence comparison shows conservation among ATP- and tryptophan-interacting residues 
between human mitochondrial TrpRS and BsTrpRS. A shared mode of tryptophan recognition 
and binding might be indicative of shared susceptibility to inhibition by indolmycin. 
The following chapters detail our efforts to uncover the structural and mechanistic basis 
for selective inhibition of bacterial TrpRS over eukaryotic TrpRS, accounting for the 106-fold 
difference in affinity. Specifically, we account for the 103-fold stronger preference of BsTrpRS 
for indolmycin than its tryptophan substrate and uncover potential means employed by 
eukaryotic cytosolic TrpRS to evade inhibition by indolmycin. Finally, we establish 
mitochondrial TrpRS as a target for indolmycin inhibition via a shared inhibition mechanism 
with BsTrpRS.   
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CHAPTER II: SELECTIVE INHIBITION OF BACTERIAL TRYPTOPHANYL-TRNA 
SYNTHETASES BY INDOLMYCIN IS MECHANISM-BASED1 
Introduction 
The accumulation of resistance in pathogenic organisms over time and with prolonged 
drug use necessitates the continued development of new anti-infective therapeutics. Such 
developments can include modifications to current drugs that are active against exploited targets 
while counteracting current resistance mechanisms or novel compounds targeted against 
underexploited targets. One group of enzyme targets that has been validated but remains 
underexploited is the class of aminoacyl-tRNA synthetases (aaRS). Aminoacyl-tRNA 
synthetases maintain the fidelity of the genetic code by ensuring the charging of tRNA with its 
cognate amino acid via the following two- step reaction:   
1) aaRS + ATP + aa         aaRS•aa-AMP + PPi   
2) aaRS•aa-AMP + tRNA          aaRS + aa-tRNA +AMP. 
All aaRS enzymes bind ATP and activate a specific amino acid by catalyzing the 
formation of an aminoacyl-5’adenylate (aa—AMP) during the first step. This is followed by 
transfer of the activated amino acid to the 3’ end of the correct tRNA. Structural and mechanistic 
differences among the different aaRS enzymes as well as orthologs of individual synthetases 
make it possible to selectively modulate the activity of specific synthetases; e.g. prokaryotic over 
                                                      
1 This chapter previously appeared as an article in The Journal of Biological Chemistry. The original citation is as 
follows: Williams TL, Yin WY, & Carter CW, Jr. (2015) Selective Inhibition of Bacterial Tryptophanyl-tRNA 
Synthetases by Indolmycin is Mechanism-Based.  
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eukaryotic TrpRS (19). This makes the aaRS enzymes attractive targets for novel anti-infective 
therapeutics. 
Any compounds intended for clinical use must be much less inhibitory against the 
eukaryotic orthologs of its intended target. Naturally occurring aminoacyl-tRNA synthetase 
inhibitors include indolmycin (TrpRS), granaticin (LeuRS), mupirocin (IleRS), and ochratoxin A 
(PheRS) (10, 19, 29, 30). Of these, mupirocin displays the required selectivity for prokaryotic 
over eukaryotic IleRS and has been developed for the treatment of infections in humans (14). 
Indolmycin produced by Streptomyces griseus displays selective inhibition for 
prokaryotic TrpRS (9 nM; E. coli) over eukaryotic TrpRS (4 mM; B. taurus) (31). Problems with 
off-target effects on tryptophan metabolism have prevented its clinical use (32). However, if we 
could understand the molecular basis for the observed inhibition and selectivity we could exploit 
this information for the rational design of antibiotics targeted against TrpRS on pathogens.  
Structurally, tryptophan and indolmycin are quite similar, with a heterocyclic indole 
moiety at the root of each ligand (Fig. 3). Indolmycin differs from tryptophan in the following 
ways:  i) the carbon that is functionally equivalent to Cβ is substituted with a methyl group, ii) 
the carbonyl carbon is part of an oxazolinone ring, iii) the hydroxyl and amine groups of 
tryptophan are replaced by the nitrogen and oxygen atoms of the oxazolinone ring, respectively, 
and iv) the -NH-CH3 moiety attached to the oxazolinone ring does not have functionally 
equivalent atoms in tryptophan.  
BsTrpRS is one of the most extensively characterized TrpRS enzymes. Mechanistically a 
Mg2+ ion is linked to what appears to be a dissociative transition state for tryptophan activation 
(20) (17) (21). During catalysis the Mg2+ ion helps compensate for the increased negative charge 
that develops on the PPi leaving group, resulting from breaking the αP---O—βP bond. The Mg2+ 
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Figure 3: Functional equivalences of tryptophan and indolmycin. Indolmycin differs from tryptophan 
in three key ways: 1) the incorporation of Cα-constituents into an oxazolinone ring, 2) a methylamino 
group extending from the oxazolinone ring, and 3) replacement of a hydrogen on Cβ with a hydrophobic 
methyl group. 
ion must move to be catalytically competent, yet no protein-metal interactions have been 
observed in any of the BsTrpRS crystal structures determined. Instead a remote allosteric 
location, the D1 switch, must undergo significant conformational change in order to promote the 
Mg2+ ion to a catalytically competent position. The metal moves closer to the PPi leaving group, 
whose charge is further stabilized in the transition state by the KMSKS loop. ATP binding is 
required for the conformational switching between the open and closed states that allows for 
catalysis. ATP-dependent induced-fit closing of the active site brings ATP ~4 Å closer to 
tryptophan in a predominantly translational movement mediated by relative movement of the 
catalytic and anticodon-binding domains.   
In the absence of ATP, tryptophan binding is promoted by hydrophobic Van der Waals 
interactions, π- π interactions with Phe 5 and a hydrogen bond between the indole nitrogen and 
Asp 132 of the specificity helix. When both substrates bind, the tryptophan substrate undergoes a 
rotational movement that brings the indole ring deeper into the binding pocket and results in 
more stabilizing interactions between tryptophan and active site residues. This change is 
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facilitated by the inward movement of the specificity helix that is not observed when only 
tryptophan is bound.   
ATP-dependent induced fit rearrangement of the active site facilitates proper ATP 
positioning in BsTrpRS, whereas molecular dynamics simulations demonstrate that tryptophan is 
required to achieve the requisite movement of the αP in HcTrpRS(22, 24). Even a modest 
substitution of tryptophanamide in place of tryptophan prevents the re-positioning of ATP.  
These findings support the idea that HcTrpRS is intrinsically better at discriminating between 
tryptophan and its structural analogues than is BsTrpRS.  
HcTrpRS uses different structural elements for substrate recognition than its prokaryotic 
orthologs (23). Such elements include an extended N-terminus with a β1-β2 hairpin structure 
shown to have a role in ATP binding as well as the amino acid activation reaction in HcTrpRS 
(25). In contrast to BsTrpRS, it is tryptophan binding that leads to induced-fit rearrangement of 
the active site in HcTrpRS. There are a greater number of binding determinants for tryptophan 
recognition as eight direct and water-mediated hydrogen bonds with polar side-chains stabilize 
tryptophan in the active site. It has been proposed that amino acid activation proceeds via an 
associative transition state in HcTrpRS with an unclear role of Mg2+ in the catalytic transition 
state (24). However, comparison of the pre-transition (2QUI) and product states (2QUJ) shows 
that, as with BsTrpRS, the Pα of ATP must move 5.3 Å to be in a position for nucleophilic attack 
by tryptophan.  
Despite mechanistic and structural differences, BsTrpRS and HcTrpRS have comparable 
tryptophan binding affinities. Yet, these inherent differences between prokaryotic and eukaryotic 
TrpRS enzymes promote the binding of indolmycin to prokaryotic TrpRSs ~1500 fold while 
protecting eukaryotic TrpRSs from such inhibition by a comparable amount. Determining the 
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structure of BsTrpRS bound by Mg2+•ATP and indolmycin allowed us to probe the structural 
basis for indolmycin inhibition and selectivity. Specifically, we examined this structure along 
with the catalytically-relevant structures of BsTrpRS and HcTrpRS deposited in the Protein Data 
Bank to answer the following questions: 1) what are the structural consequences of binding 
indolmycin; 2) why is indolmycin a tight inhibitor of prokaryotic TrpRS; and 3) why isn’t 
indolmycin an inhibitor of eukaryotic cytosolic TrpRSs? 
Experimental procedures 
Construction of pet28-His-BsTrpRS vector 
 The full-length BsTrpRS sequence was pcr-amplified from a pet11 construct made 
previously in the lab. Pcr primers contained restriction sites for BamHI and HindIII. The 
resultant pcr product was digested with BamHI and HindIII. A three-way ligation between the 
pcr product (BamHI/HindIII), dsoligo encoding for the TEV site (NdeI/BamHI) and pet28b 
(NdeI/HindIII) yielded an expression vector for His-tev-BsTrpRS. 
Expression and Purification of His-BsTrpRS 
BsTrpRS was expressed by auto-induction with BL21(DE3)pLysS cells at 37°C (33).The 
cells were pelleted at 4500 rpm for 30 minutes, resuspended in lysis buffer and frozen at -20°C. 
Upon thawing cells were sonicated and centrifuged (16000 rpm, 4°C, and 1 hour). His-BsTrpRS 
was captured from the lysate on Ni-NTA resin and eluted with 0.3 M imidazole. Purified protein 
was cleaved overnight with TEV while dialyzing out the imidazole. The cleaved protein mixture 
was passed back over a Ni-NTA column to capture both uncleaved protein and his-TEV 
protease. 
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Active Site Titration 
Active sites were titrated by following the loss of ATP to determine the fraction of 
molecules competent for catalysis (34, 35). The reaction was performed at 37°C in a final 
reaction mix containing 50 mM Hepes pH 7.5, 5000 cpm/µl (γ32P)-ATP, 10 µM ATP, 0.5 mM 
tryptophan, 5 mM MgCl2 and 0.05 U/µl pyrophosphatase. The reaction was initiated with 
enzyme at a final concentration of 3 µM. At various time points between 10 seconds and 30 
minutes, 3 µl of the reaction were added to 6 µl of quench buffer (sodium acetate pH 5.3, 1% 
SDS) and placed on ice. Three microliters of each quenched reaction were spotted onto a 
cellulose-PEI TLC plate and run in 0.75 M KH2PO4 pH 3.5 with 4 M urea to separate 32Pi and 
(γ32P)-ATP. Plates were developed using a Typhoon Imager and analyzed with ImageJ (36) and 
JMP (37).  
Michaelis-Menten Kinetics 
The incorporation of (32P)-PPi into ATP was tracked either by TLC or filter-binding after 
purification on charcoal (35). Reactions contained (32P)-PPi (5000 cpm/µl for TLC and 400 
cpm/µl for filter assay), 0.1 M Tris pH 8.0, 70 mM BME, 5 mM MgCl2, 10 mM KF, 2 mM PPi, 
2 mM ATP and tryptophan ranging from 0.3 – 100 µM. Reactions were initiated with enzyme at 
a final concentration of 30 nM. 
Indolmycin Inhibition Assays 
Inhibition assays were performed as described above; Michaelis-Menten experiments for 
tryptophan were performed in the presence of stoichiometric amounts of indolmycin to enzyme. 
Indolmycin to enzyme ratios of 1:5, 1:1 and 5:1 were used and results fitted to a competitive 
inhibition model (1) using JMP (37). Non-linear regression to eq. (1) allowed for determination 
of Km for tryptophan and Ki for indolmycin.   
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Differential scanning fluorimetry (DSF; Thermofluor) 
The effects of ATP, tryptophanamide (LTN), and indolmycin on the thermal stability of 
BsTrpRS were assessed by Thermofluor. We showed separately (Weinreb, V, Weinreb, G, 
unpublished) that DSF detects a conversion of TrpRS into a molten globule form that fully 
denatures only at higher temperature. The following saturating ligand concentrations were used 
to ensure a predominance of conformations corresponding to those observed in crystal structures: 
5 mM ATP, 5 mM MgCl2, 10 mM LTN, and 600 µM indolmycin. All reactions contained 8 µM 
BsTrpRS, 50 mM NaCl, 5 mM BME, 50 mM Hepes pH 7.5, and 0.15% Sypro-Orange in a final 
volume of 20 µl. Fluorescence intensities were determined using an Applied Biosystems 
7900HTFast Real Time (RT)PCR instrument, and data were analyzed with MATLAB 
(Mathworks) with routines developed by Visinets, Inc. The software was built as a pipeline of 
several m-files, connected to provide full analysis of the data, including thermodynamic 
characterization and presentation of statistics. Fluorescence at each data point along a melting 
curve is assumed to be the sum of contributions from two states with probabilities P1, P2 
established by thermodynamic equilibrium between the two states: 
€ 
F t( ) = a1 + b1T( )*P1 + a2 + b2T( )*P2 (2) 
where a1, and a2 are adjustable parameters representing intercepts and b1 and b2 the slopes of the 
linear dependences of the initial and final states, and T is the Kelvin temperature. The pipeline 
consists of three parts: 
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A. Reading the data from high-throughput, 384 well, RT PCR) files and transforming them into a 
matrix consisting of four columns:  i) number of the well from which temperature-dependent 
readings were taken; ii) an index representing the protein variant; and finally the data, iii) 
temperature and iv) fluorescence readings; 
B. Fitting the Thermofluor data to a thermodynamic model (eq. 3, 4).  
 
€ 
F = F0 +
a1 + b1T + (a2 + b2T)e−ΔG T( ) /RT
1+ e−ΔG T( ) /RT  
      
€ 
= F0 + a2 + b2T( )+
a1 − a2( )+ b1 − b2( )T
1+ e−ΔG T( ) /RT  (3)                                       
   
 where ΔG is the Gibbs energy difference between the two states, and e-ΔG(T)/RT is the Boltzmann 
factor that determines the state probabilities, P1 and P2: 
€ 
ΔG = ΔH Tm( )+ ΔCp * T −Tm( )−T ΔS Tm( )+ cp ln
T
Tm
⎛ 
⎝ 
⎜ 
⎞ 
⎠ 
⎟ 
⎡ 
⎣ 
⎢ 
⎤ 
⎦ 
⎥ (4) 
where ΔH and ΔS are the enthalpy and entropy changes between the states, cp is the heat capacity 
at temperature T and Δcp is the heat capacity change between the two states at the melting 
temperature, Tm.  
C. Independent determination of Tm assuming that the state probabilities, P1, P2 can be estimated 
from distances between the intersection of the melting curve with vertical lines connecting the 
extrapolated linear final and initial slopes. Data initially worked up using both methods (B) and 
(C) agreed closely, and the analysis reported here follows (C). 
 Crystallization, Data Collection, Structure Determination 
Crystals of seleno-Met- substituted BsTrpRS in complex with ATP, Mg2+, and 
indolmycin were grown by vapor diffusion against a reservoir of 1.4 M potassium citrate and 0.1 
M Hepes pH 7.4. Crystals were cryoprotected in Fomblin-Y and passed in a nitrogen airstream 
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before plunging into liquid nitrogen. Data were collected remotely at SER-CAT (Beamline ID-
22) using inverse beam geometry at 0.979 Å to obtain experimental phases from the Bijvoet 
differences, and processed with XDS (38). Phenix (39) and Coot (40) were used for phase 
determination, to interpret the map, and iteratively refine the final structure (PDB accession code 
5DK4). 
Results 
BsTrpRS binds indolmycin ~1500x more tightly than tryptophan 
Indolmycin is a competitive inhibitor of Bacillus stearothermophilus and other bacterial 
TrpRS enzymes that competes with tryptophan for binding to the enzyme’s active site. By 
conducting Michaelis-Menten experiments at increasing tryptophan concentrations in the 
presence of different indolmycin concentrations and fitting all 64 data points simultaneously to 
Eq. (1) we were able to determine KM, tryptophan, 3 µM, and Ki, indolmycin, 2 nM (Table 2). As these 
experiments were carried out under exchange conditions (41), we determined the standard free 
energy, ΔG° = -RTlnK, at 310 K for tryptophan and indolmycin binding to be 7.8 and 12.3 
kcal/mol, respectively. This translates to a free energy difference of 4.5 kcal/mol between the 
affinities of the catalytic and inhibited complexes for the indole-containing ligand.  In order to 
determine what factors account for the observed difference in binding free energy we determined 
the structure of the BsTrpRS•ATP•indolmycin ternary complex and then conducted differential 
scanning fluorimetric experiments in the presence of various ligands.  
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kcat (s
-1
) 
ΔGkcat 
(kcal/mol) 
KM,tryptophan (M) 
ΔGKm 
(kcal/mol) 
Ki,indolmycin (M) 
ΔGKi 
(kcal/mol) 
KM,tryptophan/ 
Ki,indolmycin 
31.6  
+/- 0.8 
  
-2.1 
+/- 0.01 
  
  
3.0E-06 
+/- 6.4E-07 
  
  
7.8 
+/- 0.1 
  
2.0E-09 
+/- 5.2E-10 
12.3 
+/- 0.1 
1.5E+03 
  
Table 2: Steady-state kinetic analysis of indolmycin inhibition. PPi exchange assays performed in the 
presence of saturating Mg2+•ATP with varying concentrations of tryptophan and indolmycin show 
BsTrpRS binds indolmycin ~1450 times tighter than tryptophan. The difference in free energy between 
the catalytic and inhibited complexes is ~4.5 kcal/mol. 
Indolmycin and ATP form a ternary complex with BsTrpRS 
Extensive crystallization studies conducted on BsTrpRS have revealed three distinct 
conformational states; an open conformation (ligand-free, tryptophan, low ATP (22, 26)), a 
closed pre-transition state [high ATP, ATP + tryptophanamide; (17, 22)], and a closed product 
conformation [Trp-5’AMP; (42, 43)]. A previously unpublished structure of BsTrpRS bound to 
Mg2+•ATP and indolmycin  was never deposited (44). Nevertheless, that structure was the first 
example of a series of subsequently solved structures that have been described as “Pre-transition 
state” (PreTS) structures (1MAU, 1M83; (22)). In these structures the initial ATP binding site in 
the small domain composed of the N-terminal alpha helix and the anticodon-binding domain 
closes on the remainder of the Rossmann fold, bringing the nucleotide alpha phosphate from 6.7 
Å away to within van der Waals contact distance of the tryptophan carboxyl oxygen (22).  
The new structure presented here is at higher resolution (1.9 Å vs 2.4 Å) and the 
experimental phases greatly enhanced the quality of electron density maps (Table 3, Fig. 4). 
Details of the new structure, such as the orientation of the ribose and the metal position, are quite 
similar to those observed in deposited PreTS structures, 1MAU and 1M83. Detailed differences 
that appear functionally relevant are discussed below. 
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Indolmycin induces new contacts with active-site side-chains 
Indolmycin makes contacts with the side chains of His 43, Asp 132 and Gln 147 as well 
as two water molecules (Fig. 5A). The interaction between OD2 of Asp 132 in the specificity 
helix and the nitrogen atom of the indole ring is observed when tryptophan (3.1 Å), 
tryptophanamide (3.0 Å), or indolmycin (2.9 Å) is bound. The addition of the oxazolinone group 
to the ligand allows for stabilizing interactions with His 43, Gln 147, with functionalities on 
either side of the ring, which have the effect of fixing the rotation of the ring (Fig. 5B). ND1 of 
His 43 can donate and/or accept a hydrogen bond from N2 (methylamino group) of indolmycin. 
In addition to these hydrogen bonds His 43 can form a salt bridge with OD2 of Asp 132 (2.8 Å).  
The amide group of Gln 147 forms two hydrogen bonds, one with the carbonyl oxygen of the 
oxazolinone ring (3.0 Å) and another with OD2 of Asp 146 (3.0 Å). OD1 of D146 makes a 
highly conserved hydrogen bond with the 2’OH group of ATP (2.7 Å). These side-chain 
interactions in the conserved GEDQ motif link the indolmycin and ATP binding sites, while 
reinforcing the linkage between opposite sides of the indole-binding pocket.  
Structurally, indolmycin binding also prevents the Tyr 125 rotamer switch that occurs 
upon the enzyme going from its open to closed conformation (Fig. 6A, B). During the catalytic 
cycle Tyr 125 changes hydrogen-bonding partners from His 150 (2.7 Å) in the open 
conformation to the alpha amino group (2.4 Å) of the tryptophan substrate in the closed PreTS. 
The tryptophanyl-adenylate intermediate is stabilized by two polar contacts with the hydroxyl 
group of Tyr 125 (1I6K). The inhibited state maintains the side-chain interaction between Tyr 
125 and His 150 (2.8 Å) observed in the open state.  
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                            Data Collection                                                   _                                          
Space group  
Cell Constants 
a, b, c, α, β, γ 
Resolution (Å) 
Completeness (%)a 
CC1/2 (%)a,b 
Rmeas (%)a 
Mean I/σI a 
Number of Observations 
Multiplicity 
P43212 
62.04 Å 62.04 Å 219.06 Å 
90.00° 90.00° 90.00° 
43.02 – 1.9 
99.7 (97.9) 
99.6 (93.2) 
15.3 (61.9) 
12.6 (3.3) 
464942 
15.5 
                            Refinement                                                         _ 
Rwork/Rfree (%) 
Fo, Fc correlation 
RMS (bonds) 
RMS (angles) 
Ramachandran favored (%) 
Ramachandran outliers (%) 
Average B, all atoms (Å2) 
Clash score 
PDB Entry ID 
16.6/18.7 
0.96 
0.005 
0.994 
97.0 
0.0 
32.0 
2.2 
5DK4 
aHighest resolution shell is shown in parentheses. 
bCC1/2 is the percentage of correlation between intensities from random half-datasets. 
 
Table 3: Data collection and refinement Statistics. Crystallographic data, including experimental 
phases, of seleno-methionylated BsTrpRS crystals were collected on Beamline ID-22. The final structure 
was determined to 1.9 Å resolution and refined to an Rwork/Rfree of 16.9/18.9%. 
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Figure 4: BsTrpRS forms a ternary complex with indolmycin and Mg2+•ATP in a closed 
conformation. (A) Functionally dimeric BsTrpRS crystallizes with one monomer in the asymmetric unit. 
(B) In addition to indolmycin and ATP, the active site contains a Mg2+ ion and three stable water 
molecules. The Fo-Fc omit map, derived by omitting indolmycin, ATP, Mg2+ and three water molecules 
from a final round of refinement, contoured to 4.0 σ is depicted in green.  
ATP 
Indolmycin 
Mg
2+
 
B 
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Figure 5: Hydrogen bonding and electrostatic interactions promote indolmycin binding and Mg2+ 
coordination within the active site. (A) BsTrpRS residues His 43, Asp 132, and Gln 147 make 
stabilizing contacts with indolmycin (IND) via side-chain atoms. The ATP and indolmycin binding 
subsites are linked via a hydrogen bond (2.7 Å) between Asp 146 and Gln 147 of the conserved GxDQ 
motif. (B) Mg2+ forms tight electrostatic interactions (2.0-2.3 Å) with three water molecules (red spheres) 
and an oxygen atom from each phosphate group of ATP. Two of these water molecules are within 
hydrogen bonding distance (2.6 and 2.7 Å) of indolmycin. 
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Structural modifications induced by indolmycin to the Mg2+•ATP configuration 
Superposition of the inhibited structure onto the closed PreTS structure (1MAU) gives a root 
mean-square deviation of 0.28 Å for 323 Cα pairs. For comparison the two closed PreTS 
structures, 1MAU and 1M83, have an RMSD 0.17 Å for 328 Cα pairs. The greatest structural 
difference between the PreTS and inhibited states occurs around Glu 103 – Ala 120, with an 
RMSD of 0.63 Å for these 18 residues. This mobile loop, which contains Gln 107 and Lys 111, 
is more open by ~0.5 Å in the inhibited structure, as measured from the γP of ATP to the alpha 
carbons of residues Gln 107, Lys 111, and Lys 115. The carbonyl oxygen of the Gln 107 side- 
chain accepts a hydrogen bond from the water molecule coordinated to the Mg2+ ion (2.8 Å) and 
another from NE2 of Gln 147 (3.0  Å) in the pre-transition state. Steric clashing with the 
constrained Tyr 125 rotamer prevents Gln 107 from switching rotamers in the inhibited state. As 
such, the interaction with Gln 147 is not observed. Instead, the side-chain of Gln 107 accepts a 
hydrogen bond at OE1 from a water molecule (3.0 Å) and donates a hydrogen bond at NE2 to 
another water molecule (3.3 Å). 
In the pre-transition state, the NZ atom of Lys 111 forms a salt bridge with the O1G atom 
of ATP (2.9 Å), which also forms a strong electrostatic interaction with the catalytic Mg2+ ion 
(2.4 Å). This interaction presumably is important for stabilizing the developing charge on the PPi 
leaving group released after tryptophan activation. Additionally, in the pre-transition state Lys 
111 is in position to act as a hydrogen bond donor to the one water molecule coordinated to the 
Mg2+ ion (Fig. 7). The subtle opening of this loop in the inhibited state weakens the salt bridge 
between the Lys 111 NZ atom and the O1G atom of ATP (3.4 Å) from that observed in the 
preTS. Now the closest interactions are with three water molecules (2.6, 2.8, and 2.8 Å), none of 
which are coordinated directly to the catalytic Mg2+ ion and are not shown in Fig. 7.  
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Figure 6: Comparison of ligand-free, preTS, and inhibited BsTrpRS structures. (A) Compared to the 
apo-form (pink; 1D2R), the fully occupied PreTS structure (black; 1MAU) assumes a closed 
conformation. The Cα of Tyr 125 is shifted inward by 2.4 Å and the side-chain is flipped ~45° (measured 
from OH-Ca-OH). A Mg2+ ion (black sphere) forms electrostatic interactions with ATP and one water 
molecule (salmon sphere). (B) Binding of indolmycin and ATP causes similar shifts in the backbone 
(grey) as the enzyme adopts a closed conformation. However, due to the addition of the methylamino-
substituted oxazolinone ring this movement to the closed conformation is not accompanied by a rotamer 
change of Tyr 125 in the inhibited structure. (C) Consequently, Gln 107 is constrained and is rotated 106° 
around Cβ away from the specificity helix in the inhibited state compared to the pre-transition state. 
Finally, the Mg2+ (green sphere) is shifted toward the αPO4 and has hexavalent coordination to ATP and 
three water molecules (red spheres) as compared to the preTS structure.  
 
Replacement of tryptophan(amide) with indolmycin in the active site alters the 
coordination and placement of the Mg2+ ion used during the activation step of the aminoacylation 
reaction. Presumably because its orientation is fixed by the hydrogen bonding network described 
above, the oxazolinone forms hydrogen bonds with two water molecules. Introduction of these 
two water molecules is associated with the movement of the Mg2+ ion into a hexavalent 
coordination that closely resembles stable configurations generated in quantum mechanical 
simulations of Mg2+•ATP (Shubin Liu, unpublished). 
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As is also true in the PreTS structure, the Mg2+ ion in the inhibited BsTrpRS structure 
coordinates with a non-bridging oxygen from each phosphate group and three water molecules 
(Fig. 5B, 6B), two of which are further stabilized by the presence of indolmycin. In addition to 
the three electrostatic interactions with ATP only one water molecule was seen to coordinate 
with the Mg2+ ion in the PreTS structure (1MAU) (Fig. 6A, 7). The side-chain residues that 
accept and donate hydrogen bonds to this water molecule differ between these two states (Fig. 
7). Due to the different Gln 107 rotamer and slight opening of the mobile loop around Lys 111 
these two residues no longer interact with this water molecule in the inhibited state.  
 
 
Figure 7: Differential BsTrpRS side-chain interactions with the water molecules electrostatically 
coordinated with Mg2+ in the PreTS and inhibited structures. Gln 9, Gln 107 and Lys 111 are in 
position to accept (Gln 107) or donate (Gln 9 and Lys 111) hydrogen bonds (black dashed lines) to the 
water molecule (salmon sphere) coordinated with Mg2+ (black sphere) in the PreTS (black sticks). As 
indolmycin binding leads to opening of the mobile loop containing Gln 107 and Lys 111, these residues 
are too far (red dashed lines) to form stabilizing interactions with the equivalent water molecule (red 
sphere) in the inhibited complex (grey sticks). The three water molecules (red spheres) electrostatically 
coordinated to Mg2+ (green sphere) in the inhibited complex are stabilized by interactions (cyan dashed 
lines) with side-chain atoms of residues Gln 9, Asp 146, Gln 147, and Lys 192.  
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The Mg2+ ion is closer and more central to the triphosphate moiety in the inhibited 
structure than in the PreTS structure (Fig. 6C), and makes equivalent interactions with the 
phosphate oxygen atoms. The significance of the differences in metal positions is evident from 
several measurements. (i) Metal to oxygen distances are significantly shorter (0.2 Å; P = 0.002) 
in the inhibited complexes. (ii) Movement of the divalent metal ion into closer contact with the 
ATP phosphate oxygen atoms is associated with a subtle, but statistically significant opening of 
the active site crevice between the N-terminal helix of the second crossover connection (the 
GXDQ motif), the KMSKS signature, and the mobile loop containing Lys 111. 
Ligand-induced stability changes imply cooperative sources of high indolmycin affinity 
The nature of the ligands within the active site has a significant effect on an enzyme’s 
conformation and thermal stability. For small perturbations, the fractional change in melting 
temperature (ΔTm/Tm) induced by ligand binding is proportional to the free energy change in 
stability, the proportionality constant being the enthalpy change, ΔH (45). We use this implicit 
relationship to assess the stabilizing or destabilizing effects of various ligands on the BsTrpRS 
enzyme. Binding of ATP, tryptophan or tryptophanamide stabilizes the thermal transition of 
molten globule formation by 3%, 7% and 7%, respectively (Table 4). Indolmycin enhances the 
thermal stability of BsTrpRS by 20%, increasing Tm by 13.5°C. The enhanced affinity for 
indolmycin over tryptophan results in a shift by 8°C to higher temperature in the thermal 
transition due to molten globule formation in the presence of indolmycin compared to 
tryptophan. 
The linkage between protein stability and ligand binding (46-48) implies that we can 
attribute differences in stability changes to binding affinity. Two of the stabilizing interactions 
formed between indolmycin and Mg2+-coordinated water molecules are associated with a change 
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in the metal position, relative to the ATP phosphate oxygen atoms. A key implication of the 
structural observations in Fig. 5A and Fig. 6C is that binding of indolmycin to BsTrpRS should 
be potentiated by the presence of Mg2+•ATP.  
Ligand Mg2+  Tm (°C) ΔTm (°C) (ΔTm/Tm)*100 
LF - 69.0 ± 0.2 n/a  n/a 
ATP - 71.1 ± 0.1 2.1 ± 0.2 3.0 ± 0.2% 
TRP - 74.7 ± 0.1 5.7 ± 0.3 8.2 ± 0.4% 
LTN - 74.1 ± 0.1 5.1 ± 0.3 7.4 ± 0.4% 
LTN + ATP - 74.7 ± 0.2 5.7 ± 0.2 8.3 ± 0.3% 
IND - 82.5 ± 0.2 13.5 ± 0.3 19.6 ± 0.5% 
IND + ATP - 83.3 ± 0.3 14.3 ± 0.4 20.7 ± 0.6% 
LF + 69.0 ± 0.1 n/a n/a 
ATP + 71.2 ± 0.03 2.2 ± 0.1 3.1 ± 0.2% 
TRP + 74.1 ± 0.1 5.1 ± 0.1 7.4 ± 0.1% 
LTN + 74.2 ± 0.2 5.1 ± 0.2 7.4 ± 0.3% 
LTN + ATP + 76.8 ± 0.2 7.7 ± 0.1 11.2 ± 0.2% 
IND + 82.7 ± 0.04 13.6 ± 0.2 19.7 ± 0.3% 
IND + ATP + 87.5 ± 0.1 18.4 ± 0.2 26.7 ± 0.4% 
Table 4: Thermofluor analysis of ligand-dependent stability. Substrates (ATP and tryptophan) and 
substrate analogs (LTN and IND) induce conformational changes in BsTrpRS. These changes vary with 
ligand type and confer varying degrees of thermal stability in the transition to molten globule formation. 
ATP, tryptophan, tryptophanamide, and indolmycin separately enhance the thermal stability of BsTrpRS. 
Mg2+ is required for additional stabilization by ATP of both LTN-bound and IND-bound BsTrpRS. The 
inhibited complex (BsTrpRS bound with IND and Mg2+•ATP) is the most thermal stable, with a Tm 
18.4°C and 10.7°C higher than that of ligand-free (LF) enzyme and PreTS complex, respectively.  
 
The presence/position of Mg2+ in the active site is strictly dependent on ATP, because the 
protein makes no contacts with the metal. As no direct ATP-indolmycin interactions are 
observed, we therefore expected that ATP would enhance the thermal stability of the BsTrpRS-
indolmycin complex by a larger amount in the presence, compared to the absence of Mg2+. 
Additionally, we did not expect Mg2+ to contribute to thermal stability in the absence of ATP. As 
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expected, the DSF measurements show that the BsTrpRS in complex with indolmycin and 
Mg2+•ATP has a 27% increase in melting temperature compared to ligand-free enzyme, with 
Mg2+•ATP contributing an additional 5°C of thermal stability on top of the 13.5°C provided by 
indolmycin binding. By contrast, binding of indolmycin, indolmycin+Mg2+, or indolmycin+ATP 
all elicit far smaller changes of ~20% in thermal stability, demonstrating that both Mg2+ and ATP 
are required to confer additional thermal stability to the BsTrpRS•IND complex.  
The conclusion that the metal is essential to the enhanced affinity of indolmycin to the 
pre-transition state complex can also be derived using the 3D thermodynamic cycle of 
contributions to stability from ATP, the methylamino-substituted oxazolinone ring (OXA) and 
the presence/absence of Mg2+ (Fig. 8). Differences in binding and thermal stability between 
tryptophanamide and indolmycin were attributed to the methylamino-substituted oxazolinone 
ring as this is the major structural difference between these two ligands.  
Stabilizing and destabilizing interactions are distinguished by positive and negative non-
additivity, respectively. If thermal stability were unaffected by interactions between the ligands, 
then we expect the effects of binding multiple ligands, e.g. ATP and LTN, to be additive and 
binding one ligand not to be affected by the presence of a second ligand. Thus: 
€ 
ΔTm ATP( )+ ΔTm LTN( ) = ΔTm ATP + LTN( )    (5) 
€ 
ΔTm LTN( ) = Tm LTN( )−Tm LF( ) ( ) ( )ATPTLTNATPT mm −+=             (6) 
An interaction between the ligands would introduce a term, ΔTm,int, to describe the non-additivity 
(49), and:  
€ 
ΔTm ATP( )+ ΔTm LTN( )+ ΔTm,int = ΔTm ATP + LTN( )   (7)  
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Figure 8: Contributions of Mg2+, ATP, indolmycin and tryptophanamide to the thermal stability of 
BsTrpRS. TrpRS enzymes require a Mg2+ ion for tryptophan activation. While Mg2+ does not change the 
thermal stability of BsTrpRS on its own, its presence or absence significantly impacts the interaction of 
ATP with both tryptophanamide (LTN) and indolmycin (IND). In the absence of Mg2+ (top row) both the 
ATP-LTN and ATP-IND interactions lower the fractional change in Tm by 2% from its expected value. 
In the presence of Mg2+ (bottom row) the interaction between ATP and LTN is insignificant, while the 
ATP-IND interaction raises the Tm 4% higher than expected.  As expected from the crystal structure, the 
Mg2+ -dependent ATP-IND interaction is mediated through the oxazolinone moiety of indolmycin. 
 
In the absence of Mg2+ there is no significant ATP•OXA interaction, and binding either 
IND or LTN reduces the effect of ATP on Tm by ~1.5°C. The ATP•LTN and ATP•IND 
interactions are both destabilizing, i.e. the doubly-liganded complexes melt at lower 
temperatures. In contrast, addition of Mg2+ stabilizes the interactions of ATP with LTN and IND 
to varying degrees. In the case of LTN•ATP, addition of Mg2+ compensates for the destabilizing 
ATP•LTN interaction such that the interaction is no longer significant. The metal compensates 
for the -1.3°C destabilizing ATP•IND interaction and allows for an additional stabilizing 
interaction of 2.6°C. Thus, the ΔTm (ATP•OXA) interaction is comparable to that of the ΔTm 
(ATP•IND) interaction. The crystal structure suggests that the stabilizing effect of Mg2+ on the 
interaction between ATP and indolmycin is mediated through the oxazolinone ring, whose 
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orientation is, in turn, stabilized by hydrogen bonds to His 43 and Gln 147 as discussed in a 
previous section.   
Mutations to residues in the D1 Switch alter the indolmycin:tryptophan selectivity ratio  
Residues I4, F26, L29, Y33, C35, F37 and I140 within the D1 switch region of BsTrpRS 
rearrange to form new Delaunay tetrahedra during Mg2+-assisted catalysis and are critical for 
protein-metal interactions in the transition state for tryptophan activation (50). Furthermore, 
mutations to these residues lead to altered tryptophan-tyrosine specificity ratios. In light of the 
observed stabilizing oxazolinone-ATP interaction that is mediated via Mg2+ we wondered if D1 
switch mutants displayed differential indolmycin inhibition kinetics. Steady-state PPi-exchange 
assays conducted with varying indolmycin and tryptophan concentrations allowed us to 
determine kcat, KM tryptophan, and Ki indolmycin for four BsTrpRS variants (Table 5). 
BsTrpRS kcat (s-1) KM, trp (M) Ki, ind (M) 
I4V F26L 
 Y33F F37I 35.3 ± 1.2 2.2E-06 ± 6.0E-07 5.5E-09 ± 2.2E-09 
Y33F F37I 21.6 ± 1.3 2.2E-05 ± 6.3E-06 4.5E-09 ± 1.3E-09 
F26L F37I 29.9 ± 1.0 1.5E-05 ± 2.8E-06 7.0E-09 ± 1.5E-09 
F26L Y33F 26.4 ± 0.6 9.0E-06 ± 2.2E-06 8.0E-09 ± 2.4E-09 
Table 5: Steady-state kinetic analysis reveals differential indolmycin and tryptophan binding by D1 
switch mutants. 
 
All four variants tested had altered catalytic efficiencies compared to wild-type BsTrpRS. The 
Y33F F37I and I4VF26LY33FF37I mutants were the least and most efficient variants, 
respectively. Both double mutants containing the F37I substitution bound tryptophan an order of 
magnitude weaker than native BsTrpRS. While the affinity of the quadruple mutant for 
tryptophan did not change, its affinity for indolmycin was ~2.7 times weaker. In contrast, the 
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observed ~2-fold weaker indolmycin binding of the Y33F F37I BsTrpRS variant was 
accompanied by a 10-fold reduction in tryptophan affinity. The F26LF37I and F26LY33F double 
mutants had comparable changes in their affinities for tryptophan and indolmycin such that their 
selectivity ratio did not differ from wild-type (Fig. 9). 
 
Figure 9: D1 switch residues contribute to tryptophan versus indolmycin selectivity. Compared to 
native BsTrpRS (WT; red bar), variants containing substitutions at residues involved in long-range 
coupling to the catalytic Mg2+ ion display differential inhibition kinetics. The Y33FF37I variant has the 
highest preference for indolmycin due mainly to decreased tryptophan affinity. Reduced indolmycin 
binding results in the quadruple mutant having the smallest (400-fold) difference between tryptophan and 
indolmycin affinities.  
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Discussion 
An array of crystal structures of both BsTrpRS and HcTrpRS provide snapshots of the 
enzymes along their catalytic paths and demonstrate the conformational changes that result from 
binding of various ligands (22, 23, 26). From these structures it is evident that HcTrpRS uses a 
greater number of binding determinants for tryptophan recognition and that binding of 
tryptophan causes an induced-fit rearrangement of the active site in HcTrpRS, but not BsTrpRS. 
Here we discuss possible structural and mechanistic reasons for the tight binding of indolmycin 
to BsTrpRS and the inability of indolmycin to inhibit eukaryotic TrpRSs.  
Why is indolmycin a high-affinity inhibitor of bacterial TrpRS? 
There are no drastic global changes between pre-transition state (1MAU) and the 
indolmycin-inhibited (5DK4) BsTrpRS structures. We propose that subtle, mechanistically 
relevant differences in the active-site metal configuration account for the ability of indolmycin to 
inhibit BsTrpRS as tightly as it does. We observe stronger Mg2+--ATP and weaker BsTrpRS--
ATP interactions (Fig. 8), as well as altered Mg2+ coordination and placement in the inhibited 
state (indolmycin + Mg2+•ATP; Figs. 5B, 6), compared to the pre-transition state 
(tryptophanamide + Mg2+•ATP) structure. We attribute these differences to the replacement of 
tryptophanamide with indolmycin which varies mainly at the methylamino-substituted 
oxazolinone ring of indolmycin. Interactions between His 43, Gln 147, and indolmycin restrict 
the oxazolinone ring orientation, thereby reducing the entropy of the α-carbon mimic in the 
inhibited complex compared to the pre-transition state complex. This unfavorable entropy 
change is compensated by the enthalpy from additional hydrogen bonds formed between the 
Mg2+-coordinated water molecules and the oxazolinone nitrogen and carbonyl oxygen atoms as 
well as the interaction with His 43.  
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These hydrogen bonds stabilize the water molecules that are also tightly coordinated to 
the catalytic Mg2+ ion. Functional groups of the α-carbon atoms of tryptophan and 
tryptophanamide can adopt alternative conformations that are similar in energy, none of which 
allow for completion of the Mg2+ coordination sphere. We conclude from these observations that 
completion of that coordination sphere allows the metal to form significantly tighter interactions 
with all three phosphate oxygen atoms, and hence that indolmycin stabilizes a ground-state 
Mg2+•ATP configuration, opposing the tendency of the PreTS state to promote the metal to a 
high energy state that assists in transition-state stabilization.   
  Further, the oxazolinone ring of indolmycin, stabilized by hydrogen bonds with His 43 
and Gln 147, prevents the rotamer switch of Tyr 125 in the specificity helix that is part of the 
structural transition from the open to closed state. To avoid a steric clash with the constrained 
Tyr 125 residue Gln 107 likewise does not switch rotamers in the presence of indolmycin. Gln 
107 is part of a highly mobile loop that shows a subtle but significant opening in the inhibited 
state compared to the pre-transition state. This opening results in the weakening of ATP--
BsTrpRS interactions, specifically those between Lys 111 and the γ-phosphate group.  
In the catalytically-competent PreTS configuration, coordination by lysine residues of the 
phosphate oxygen atoms promotes the metal to an activated, less stable state with weaker 
interactions to the three phosphate oxygen atoms and prevents the Mg2+ ion from assuming a 
lower energy position with stronger contacts to ATP.   The positively charged NZ atom of Lys 
111 competes with the Mg2+ ion for stabilization of a negatively charged oxygen atom (Oγ) of 
the γ-phosphate group. In the PreTS state the Mg2+--Oγ and Lys 111—Oγ distances are 2.4 Å 
and 2.9 Å, respectively.  
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Substitution by indolmycin for tryptophanamide simultaneously weakens the Lys 111—
Oγ (3.4 Å) interaction and strengthens that between that oxygen atom and the Mg2+ ion (2.2 Å). 
Additionally, the 0.4 Å shift in Mg2+ placement along with the opening of the mobile loop 
around Lys 111 allows for tight, hexavalent Mg2+ coordination, accompanied by stronger, more 
nearly equivalent interactions between Mg2+ and the three ATP phosphate groups. 
Mutation of His 43 results in indolmycin-resistance 
When both tryptophanamide and ATP are bound, the His 43 side-chain switches from 
one rotamer to another in the transition from open to closed, PreTS state and back again in the 
closed, product state. This rotamer switch does not occur when the active site is bound to AMP, 
PPi and tryptophan (51). In the PreTS (Mg2+•ATP + LTN) and inhibited (Mg2+•ATP + IND) 
states, NE2 of His 43 interacts with OD2 of Asp 132. In all other observed states, NE2 of His 43 
forms an interaction with the carbonyl oxygen of Tyr 125. His 43 also contributes to indolmycin 
binding via ND1. This re-orientation of His 43 appears correlated with the succession of ligands 
most similar to the putative catalytic reaction path, and it may thus also be functional. 
Several groups have identified mutations that confer high-level indolmycin resistance 
(52-54). One of the mutant sites, His 43, is of direct interest in the context of the present 
inhibited structure, which furnishes a semi-quantitative explanation for the mutational effects at 
position 43. We have implicated His 43 in a hydrogen bond network that requires hydrogen 
bonds to both indole nitrogen atoms that stabilize the orientation of the plane of the oxazolinone 
ring of indolmycin. Fixing the orientation of the ring consequently allows formation of a full 
hexacoordinated environment for the catalytic Mg2+ ion, which we have shown accounts for the 
additional stabilization of the indolmycin•Mg2+•ATP complex.  
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Indolmycin inhibition of the B. stearothermophilus TrpRS H43N mutant is weaker by 3.5 
kcal/mole than that of the native enzyme (55). Depending on the stabilization energy provided by 
these two hydrogen bonds and their coupling, we would predict that an H43N mutant would lose 
2 to 4 kcal/mol of binding energy compared to wild-type enzyme. All rotamers of an asparagine 
substitution at position 43 would result in the loss of two of the three hydrogen bonds observed 
in the network between indolmycin, His 43 and Asp 132. Similarly, the homologous H48Q 
mutation in Streptomyces coelicolor similarly appears incapable of forming both hydrogen bonds 
we observe for His 43 (54). 
Modeling reveals why indolmycin is a weak inhibitor of eukaryotic cytosolic TrpRS  
The selectivity ratio (SR) of indolmycin for cytosolic B. taurus (Bt)TrpRS versus 
BsTrpRS is 106-fold in favor of BsTrpRS binding. This selectivity factor far surpasses those of 
most therapeutic drugs, including trimethoprim (SR rat/T. gondii DHFR = 49) and metoprolol 
(SR β2/β1 adrenergic receptor = 6.0) which treat toxoplasmosis and cardiovascular disease, 
respectively (56, 57). This dramatic selectivity arises by enhancing indolmycin binding 
recognition by BsTrpRS as we have just shown, while reducing eukaryotic cytosolic TrpRS 
affinity by similar magnitudes. HcTrpRS shares 93% sequence identity with BtTrpRS and is 
therefore highly likely to have a comparably weak millimolar affinity for indolmycin. Interest in 
developing indolmycin as a lead compound for anti-infective therapy, as well as the extensive 
kinetic and structural studies conducted on HcTrpRS, led us to examine the repertoire of 
deposited HcTrpRS structures with the purpose of identifying potential means by which 
eukaryotic cytosolic TrpRS enzymes evade inhibition by indolmycin (23, 25, 27, 58).  
Whereas BsTrpRS uses an induced fit mechanism for ATP binding, HcTrpRS uses 
induced fit for tryptophan binding. Binding of tryptophan to BsTrpRS is stabilized by one 
 38 
 
 
 
hydrogen bond between the indole nitrogen of tryptophan and OD2 of Asp 132 and π-π 
interactions with Phe 5. Meanwhile HcTrpRS makes seven direct and water-mediated contacts to 
its tryptophan substrate. The determinants for tryptophan binding to HcTrpRS include Glu 199, 
which has a direct and water-mediated interaction with the α-amino group of tryptophan (Fig. 
10A). Modeling of indolmycin into the amino acid binding site introduces steric clashes between 
indolmycin and Glu 199 (Fig. 10B). Furthermore, Glu 199 cannot adopt an alternative rotamer 
conformation without introducing additional clashes between Glu 199 and Thr 196, Trp 203 or 
Phe 280. Besides clashing with Glu 199, this indolmycin conformer would not form any of the 
hydrogen bonds observed when tryptophan is bound, aside from the bifurcated hydrogen bond 
with the indole nitrogen, Tyr 159 and Gln 194. These interactions are preserved because 
indolmycin was modelled into the active site by overlaying its indole moiety with that of 
tryptophan (2QUH).  
Indolmycin can be modelled into the active site of HcTrpRS by rotating the oxazolinone 
ring away from Glu 199 to an orientation perpendicular to the indole moiety (Fig. 10B). While 
this indolmycin conformer does not clash with active site residues, it does disrupt the hydrogen 
bonding pattern used by the cytosolic enzyme to identify tryptophan as the bound substrate. The 
α-amino group of tryptophan, which is protonated at physiological pH, is recognized by Glu 199, 
Gln 284 and Gln 313 (Fig. 10A). Each of these residues acts a hydrogen bond acceptor and the 
negatively charged carboxylate of Glu 199 forms additional electrostatic interactions with the 
amino group. According to our model the side chain amide group of Gln 284 would act as a 
hydrogen bond donor for the cyclic oxygen atom in indolmycin that is in the equivalent position 
of the α-amino group (Fig. 10B). While Glu 199 cannot form a salt bridge with indolmycin it can  
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Figure 10: Steric hindrance and altered hydrogen bonding pattern allow HcTrpRS to discriminate 
between tryptophan and indolmycin. (A) The electrostatic and hydrogen bonding interactions that 
facilitate specific recognition and binding of tryptophan (TRP) to HcTrpRS (2QUH) are shown in yellow 
dashes. (B) Indolmycin (IND; yellow and pink sticks) from the BsTrpRS complex was modelled into the 
tryptophan binding site of HcTrpRS (2QUH) so the indole moieties superimposed. This maintained the H-
bonding interactions between the indole nitrogen and Tyr 159 and Gln 194. Rigid-body modelling shows 
none of the interactions important for tryptophan substrate recognition/binding can form between active 
site residues and indolmycin (yellow sticks).  Additionally, rotating the oxazolinone ring away from Glu 
199 eliminates a prominent steric clash between the methylamino group of indolmycin and the side chain 
carboxylate group of Glu 199. This alternate indolmycin conformation (pink sticks) allows for more 
hydrogen bonding interactions between indolmycin and active-site residues, though the nature of these 
interactions is different from those observed upon tryptophan binding. Modelling suggests that these 
altered interactions allow HcTrpRS to reject indolmycin as a substrate. 
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instead share a bifurcated hydrogen bond from the methylamino group nitrogen with Gln 313. 
This nitrogen can accept a hydrogen bond from the hydroxyl group of Tyr 316. 
Finally, Lys 200 cannot form a salt bridge with indolmycin as it does with the tryptophan 
carboxylate. This electrostatic interaction is also missing when tryptophanamide is bound in 
place of tryptophan and appears to be critical for progression from the pre-transition state to 
transition state, as this is the only interaction used for tryptophan substrate recognition and 
binding that cannot form when tryptophanamide occupies the active site. Indolmycin differs 
from tryptophan by a greater degree than does tryptophanamide. The inability of indolmycin to 
fully retain the tryptophan-HcTrpRS side-chain interactions, including the salt bridge with Lys 
200, allows HcTrpRS to discriminate between tryptophan and the inhibitor. For these reasons a 
stable HcTrpRS •ATP•indolmycin complex is ~1000 less likely to form than that of HcTrpRS 
•ATP•tryptophan. Contrastingly, BsTrpRS, which has a 103-fold higher affinity for indolmycin 
over tryptophan, is ~1500 more likely to form a stable, inhibited complex than a catalytically-
competent tryptophan-bound complex.   
Conclusion 
 
In this work, we determined the structural basis for high-affinity inhibition of BsTrpRS 
by indolmycin. The simultaneous binding of indolmycin and Mg2+•ATP results in i) movement 
of the Tyr 125 and Gln 107 side chains, ii) opening of the mobile loop containing Lys 111, iii) 
displacement of the Mg2+ ion by 0.4 Å, iv) hexavalent metal coordination, v) stronger, nearly 
equivalent electrostatic interactions of Mg2+ with an oxygen from each phosphate group of ATP, 
and vi) weaker coordination of phosphate group oxygen atoms by active-site lysine residues. 
These changes are reinforced by the hydrogen bonding interactions of Gln 147, His 43, and 
Mg2+-coordinated water molecules with indolmycin. We propose that weaker coordination by 
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lysine residues of the phosphate oxygen atoms and stronger Mg2+--ATP interactions induced by 
indolmycin binding allow the Mg2+ ion to settle into a lower energy state, thereby significantly 
increasing affinity by preventing activation of the metal required for use in amino acid 
activation. 
Author contributions—CWCjr and TLW conceived the experimental plan, based on previous 
work by WYY. TLW carried out all experimental work, analyzed the data and wrote the paper in 
consultation with CWCjr and WYY. 
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CHAPTER III: HUMAN MITOCHONDRIAL TRYPTOPHANYL-TRNA SYNTHETASE 
UTILIZES CONSERVED ELEMENTS TO BIND INDOLMYCIN AND ATP 
 
Introduction 
 
Increasing drug resistance places great demand on the development of antibiotics active 
against novel targets. Successful candidates should be assessed for off-target effects including 
the potential for deleterious interactions with mitochondrial proteins. Mitochondrial dysfunction 
is often a detrimental consequence of prolonged antibacterial and antiviral therapeutics due, in 
part, to unintended drug interactions with host mitochondrial homologs of the pathogenic target 
proteins (59-61). Mitochondria have retained many conserved proteins, pathways and processes 
from their prokaryotic ancestors. Dysregulation or inactivation of mitochondrial enzymes, most 
of which are nuclear-encoded, has great potential for debilitating ATP production. 
One under-utilized target for antibacterial action is tryptophanyl-tRNA synthetase. We 
demonstrated in Chapter 2 that mechanistic differences allow indolmycin, a natural TrpRS 
inhibitor, to selectively bind Bacillus stearothermophilus (Bs) TrpRS 106-fold over eukaryotic 
cytosolic TrpRS (18). Specifically, BsTrpRS uses an acidic residue, Asp 132, to recognize the 
indole nitrogen and bind indolmycin (and substrate tryptophan) to a largely hydrophobic pocket. 
In the presence of bound tryptophan a catalytic Mg2+ ion electrostatically coupled to each 
phosphate group of ATP becomes activated for participation in catalysis (17, 20, 21). The 
methylamino-substituted oxazolinone ring of indolmycin prevents Mg2+ activation due to stable, 
hexavalent Mg2+ coordination, stronger Mg2+•ATP interactions, and weaker TrpRS•ATP 
 43 
 
 
 
interactions (18). Sequence variations, specifically alanine substitution for the second lysine of 
the conserved KMSKS motif and shifting of catalytically-important residues to the N-terminal 
extension, altered ATP binding and Mg2+•ATP coordination, as well as a greater number of  
binding determinants for tryptophan recognition prevent indolmycin from being a tight-binding 
inhibitor of HcTrpRS (23, 25, 27). 
Although the human mitochondrial (Hmt) TrpRS enzyme was identified and kinetically 
characterized over 15 years ago, structural information about the enzyme remains lacking (28). 
As such, little is known about how the enzyme recognizes its substrates. Based solely on primary 
sequence comparison, we know that HmtTrpRS has retained the aspartic acid residue of the 
specificity helix shown to recognize tryptophan in BsTrpRS while showing sequence variation at 
positions involved in tryptophan binding by HcTrpRS (Fig. 11). Additionally, HmtTrpRS has the 
canonical KMSKS sequence important for ATP binding and lacks the N-terminal extension 
acquired by HcTrpRS (Fig. 11). From this we expect HmtTrpRS to utilize similar determinants as 
BsTrpRS for tryptophan and ATP binding and to, similarly, be targeted for inhibition by 
indolmycin. 
Here, we provide structural, kinetic and thermodynamic evidence that indolmycin is a 
tight-binding inhibitor of HmtTrpRS. Additionally, we use the sole structure of HmtTrpRS 
determined as part of this work to describe structural details which support a shared mechanism 
for indolmycin inhibition between HmtTrpRS and BsTrpRS as well as utilization of conserved 
elements in the recognition/binding of ATP and indolmycin that imply a shared mechanism for 
tryptophan activation. 
 
  
 44 
 
 
 
Experimental procedures 
 
Construction of HmtTrpRS expression plasmids and mutagenesis  
 
 The codon-optimized gene for human mitochondrial (Hmt) tryptophanyl-tRNA 
synthetase (TrpRS) was purchased from GenScript in the puc57 plasmid. Translation of this gene 
yields a protein that lacks the putative mitochondrial targeting sequence, residues 1-18, identified 
by Jorgensen et al (28). To facilitate purification we decided to add an N-terminal 6x-His tag that 
could be removed by Tev protease. This was achieved via a three-way ligation with 
EcoRI/HindIII digested pet28a, HindIII digested pcr product of HmtTrpRS amplified from puc57 
plasmid with primers L19-F and Hmt-Hd3-R, and the  annealed Tev-F and Tev-R oligos (Table 
6). This construct was used as a template to introduce amino acid substitutions such as H48T and 
K226A along with the primers listed in Table 6 in accordance with the Invitrogen GeneTailor 
Site-Directed Mutagenesis System. The Δ 1-33 variant was created by three-way ligation as 
described above following pcr amplification with primers K34-F and Hmt-Hd3-R. Finally, 
codons corresponding to residues 1-18 were added to the original Δ 1-18 gene via three 
successive pcr amplifications using the primers MTS1-3 and Hmt-Hd3-R. The final pcr product 
digested with BamHI and HindIII was ligated with pet28. The sequences for all constructs were 
confirmed by DNA sequencing. 
Heterologous Expression of 6xHis-HmtTrpRS 
 
All 6xHis-HmtTrpRS variants were co-expressed in BL21(DE3) cells with chaperones 
GroEL/ES and induced by auto-induction (33). First, BL21(DE3) cells bearing the pGro7 
plasmid (Takara) were made competent by CaCl2 treatment. The pGro7 plasmid allows for 
arabinose-induced expression of GroEL/ES chaperones and confers chloramphenicol resistance. 
Next, 50µl of these cells were freshly transformed with plasmid DNA. Following a 1 hour   
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Figure 11: Structure-based sequence alignment of BsTrpRS, HmtTrpRS and HcTrpRS. Following 
superimposition of relevant BsTrpRS, HmtTrpRS and HcTrpRS structures USCF Chimera was used to 
generate a structure-based sequence alignment of the three enzymes. This alignment facilitates 
comparison of residues used for substrate binding. The red and blue triangles point to residues that 
interact with tryptophan when tryptophan alone is bound to BsTrpRS and HcTrpRS, respectively. The 
final image was generated using ESPript 3.0. 
 
 46 
 
 
 
Designation Sequence 5’  3’ Purpose 
Tev-F 
Tev-R 
aattcgagaacctctacttccagggc 
gccctggaagtagaggttctcg 
Add TEV cleavage site 
by oligo-annealing 
L19-F ctgcataaaggtagcgcggcg Amplify HmtTrpRS gene 
Hmt-Hd3-R gattacgccaagcttatcactacaggaaac Introduce HindIII site after stop codon 
K34-F aaaaaacgtgtgttctctggcattcaaccg  
Remove codons for 
residues 19-33 
MTS1 
MTS2 
MTS3 
 
tggtccttcatcagggcgttgcataaaggtagcgcggcgggc 
atgaggaaggcaagggagaggtggtccttcatcagggcgttgcataaaggt 
gaacggatccatggcactgcacagcatgaggaaggcaagggagaggtggtccttcatc 
 
Add mitochondrial 
targeting sequence by 
pcr in three reactions 
Q42A-F 
Q42A-R 
gtgttctctggcattGCAccgacgggcat 
aatgccagagaacacacgttttttgg 
Mutate glutamine to 
alanine at position 42 
H48T-F 
H48T-R 
ccgacgggcattctgACTctgggcaact 
cagaatgcccgtcggttgaatgccag 
Mutate histidine to 
threonine at position 48 
K145A-F 
K145A-R 
caccaatggaaagccGCAaccacgaaac 
ggctttccattggtgcagatgctgc 
Mutate lysine to 
alanine at position 145 
K145Q-F caccaatggaaagccCAAaccacgaaac 
Mutate lysine to 
glutamine at position 
145 
D181A-F 
D181A-R 
gtcccggtgggtgaaGCTcaggtccaac 
ttcacccaccgggacatgggtgctt 
Mutate aspartic acid to 
alanine at position 181 
K226A-F 
K226A-R 
cgtgatccgtcggccGCAatgagcaaatc 
ggccgacggatcacgcagtgattta 
Mutate lysine to 
alanine at position 226 
 
K226Q-F 
 
cgtgatccgtcggccCAAatgagcaaatc 
Mutate lysine to 
glutamine at position 
226 
K229A-F 
K229A-R 
tcggccaaaatgagcGCAtctgatccgg 
gctcattttggccgacggatcacgc 
Mutate lysine to 
alanine at position 229 
K229Q-F tcggccaaaatgagcCAAtctgatccgg 
Mutate lysine to 
glutamine at position 
229 
K226AK229A cgtgatccgtcggccGCAatgagcGCAtctgatccggac 
Mutate lysine to 
alanine at positions 226 
and 229 
K226QK229Q cgtgatccgtcggccCAAatgagcCAAtctgatccggac 
Mutate lysine to 
glutamine at positions 
226 and 229 
Table 6: Primers and oligos used for gene amplification and mutagenesis by pcr.   
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recovery with shaking at 37°C, transformed cells were allowed to grow overnight in 4 mL of 
ZYM-505 media supplemented with 100 µg/mL kanamycin, 34 µg/mL chloramphenicol, and 
0.05% arabinose. The next morning, the overnight culture was diluted 1000-fold into ZYM-5052 
supplemented with 100 µg/mL kanamycin, 34 µg/mL chloramphenicol, and 0.05% arabinose. 
Larger cultures were shaken at 220 rpm until reaching an OD = 1, at which point the temperature 
was shifted from 37°C to 18°C and allowed to grow for another 16 hours. The cells were 
harvested at 4500 rpm for 30 minutes and bacterial pellets frozen at -20°C for at least 2 hours 
before lysis. 
Purification of His-HmtTrpRS 
 
Upon thawing, cells were resuspended in lysis buffer (50 mM Hepes, 0.3 M NaCl, 10 
mM BME, 1 M urea, 10% glycerol, 1% triton X-100, pH 8.0), sonicated and centrifuged (16000 
rpm in SS34 rotor, 4°C, and 1 hour). His-HmtTrpRS was captured from the lysate on Ni-NTA 
resin and eluted with 0.3 M imidazole. Purified protein was cleaved overnight with TEV protease 
while dialyzing against 50 mM Hepes, 0.2 M NaCl, 10 mM BME, pH 7.4. The cleaved protein 
mixture was passed back over a Ni-NTA column to capture both uncleaved protein and his-TEV 
protease. Size exclusion chromatography on a Superdex 200 column was used as a final 
purification step for HmtTrpRS. Fractions containing HmtTrpRS were pooled and concentrated 
using Amicon concentrators with MWCO 10,000. 
Active Site Titration 
Active sites were titrated by following the loss of (32Pγ)-ATP to determine the fraction of 
molecules competent for catalysis as described by (34, 35). Plates were developed using a 
Typhoon Imager and analyzed with ImageJ (36) and JMP (37).  
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Michaelis-Menten Kinetics 
 
The incorporation of (32P)-PPi into ATP was tracked by TLC. Reactions contained 5000 
cpm/µl (32P)-PPi, 0.1 M Tris pH 8.0, 70 mM BME, 5 mM MgCl2, 10 mM KF, 2 mM PPi, 2 mM 
ATP and tryptophan ranging from 1-1500 µM. When ATP was varied from 60 - 2000 µM 
tryptophan was used at a final concentration of 2 mM. Reactions were initiated with enzyme and 
carried out at 37°C. 
Indolmycin Inhibition Assays 
Inhibition assays were performed as described above; Michaelis-Menten experiments for 
tryptophan were performed in the presence of stoichiometric amounts of indolmycin to enzyme. 
Indolmycin to enzyme ratios of 1:5, 1:1 and 5:1 were used and results fitted to a competitive 
inhibition model (I) using JMP (37). This setup allowed for determination of Km for tryptophan 
and Ki for indolmycin.  
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Differential scanning fluorimetry (DSF; Thermofluor) 
The effects of ATP, tryptophan, tryptophanamide (LTN), and indolmycin on the thermal 
stability of HmtTrpRS were assessed by Thermofluor. The following saturating ligand 
concentrations were used: 10 mM ATP, 10 mM MgCl2, 3 mM LTN, and 3 mM indolmycin. All 
reactions contained 8 µM HmtTrpRS, 100 mM NaCl, 5 mM BME, 1 M guanidine hydrochloride, 
50 mM Hepes pH 7.5, and 0.15% Sypro-Orange in a final volume of 20 µl. Temperature-
dependent fluorescence intensities from 25-99°C were determined using an Applied Biosystems 
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7900HTFast Real Time (RT)PCR instrument, and data were analyzed with MATLAB 
(Mathworks) with routines developed by Visinets, Inc as described in the previous chapter. 
Circular Dichroism (CD) 
The CD spectrum of ligand-free HmtTrpRS was recorded from 190-280 nm using a Jasco 
J-815 CD spectrometer. The sample contained 10 µM HmtTrpRS, 50 mM Hepes, 1 mM BME, 
150 mM NaF, pH 7.4 with and without 1 M guanidine hydrochloride in a final volume of 200 µl. 
Following collection of the CD spectrum, the sample was used for thermal melting analysis at 
0.1 mm path length from 4-95°C. 
Isothermal Titration Calorimetry (ITC) 
Experiments were carried out at 37°C. The sample cell was filled with HmtTrpRS in 50 
mM Na2HPO4, 150 mM NaCl, 10 mM BME, pH 7.4 with and without 10 mM MgCl2 and 5 mM 
ATP. Using the MicroCal Auto-iTC200 system, ligands were added by a series of 20-2 µl 
injections with 180 seconds between each injection and a reference power of 8 µcal/sec. Twenty-
seven 1.5 µl injections were used to titrate HmtTrpRS pre-bound to Mg2+•ATP with indolmycin. 
Data were analyzed using a one-site model in Origin (OriginLab, Northampton, MA). 
Crystallization, Data Collection, Structure Determination 
Crystals of HmtTrpRS in complex with ATP, indolmycin and Mn2+ were grown by vapor 
diffusion against 25% glycerol, 20% Peg5000 and 0.1 M NaOAc. As the crystal growth solution 
was cryoprotective, crystals did not require further handling before plunging into liquid nitrogen. 
Data were collected at Southeast Regional Collaborative Access Team (SER-CAT) 22-ID 
beamline at the Advanced Photon Source, Argonne National Laboratory.  Supporting institutions 
may be found at www.ser-cat.org/members.html. The structure (PDB accession code 5EKD) was 
determined using molecular replacement with the BsTrpRS structure (5DK4) as a starting model. 
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The initial model was improved using cycles of Coot (40) rebuilding and refinement using 
Phenix (39). 
Results 
 
        Co-expression with GroEL/ES enhances both expression and solubility of dimeric HmtTrpRS 
 Initial attempts to express 6xHis-HmtTrpRS in BL21(DE3)pLysS resulted in less than 
5% of the HmtTrpRS being soluble (Fig. 12A), with final yield of 2 mg HmtTrpRS per 2 liters. 
Using auto-induction instead of IPTG increased total HmtTrpRS expression without improving 
solubility (Fig. 12A). In an effort to promote the production of soluble HmtTrpRS, we assessed 
the effect of co-expression with various chaperones on the solubility of HmtTrpRS. Figure 12B 
shows how chaperone co-expression influenced both expression and solubility, with GroEL/ES-
expressing cells producing more total HmtTrpRS and the highest fraction of soluble HmtTrpRS. 
Chaperone co-expression and auto-induction routinely resulted in ~20 mg of HmtTrpRS per 1 L 
culture.  
We employed the 6xHis-tag to isolate HmtTrpRS from the soluble bacterial proteins on 
Ni-NTA resin. Most of the tagged-HmtTrpRS bound the Ni-NTA with minor contaminants that 
were eliminated by size exclusion chromatography on a Superdex 200 column (Fig. 12C). The 
elution profile of HmtTrpRS demonstrates that it passes through the Superdex 200 resin in a 
manner expected of a protein with a calculated molecular weight of 80 kDa. TrpRS enzymes are 
functional dimers and the calculated molecular weight correlates well with the expected size (76 
kDa) of the HmtTrpRS dimer. Active site titration experiments tracking the consumption of ATP 
over time show that each active site of the HmtTrpRS dimer utilizes ATP to form the 
tryptophanyl-5’AMP (Fig. 13). If we use the dimeric enzyme concentration to calculate the 
fraction of active sites, we derive a number between 1.5 and 2. However, if we use the  
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Figure 12: Auto-induction and chaperone co-expression increase the expression and solubility of 
dimeric HmtTrpRS. A) Electrophoresis of whole-cell lysates (wcl) and soluble fractions (sol) showed 
that while auto-induction (AI) enhanced the overall expression of HmtTrpRS it did not increase the 
fraction of soluble enzyme compared to the IPTG sample. B) Immunoblot analysis using an anti-His-tag 
antibody demonstrated that co-expression of HmtTrpRS by auto-induction with the GroEL/ES yielded the 
highest overall expression and soluble fraction of HmtTrpRS. C) Size-exclusion chromatography allowed 
us to determine that HmtTrpRS exists as dimer in solution. Gel inset shows purity of the final protein 
sample. No other proteins were identified when up to ~6 µg of total protein was separated by SDS-PAGE 
followed by staining of the gel with Coomassie Blue (gel inset).  
A 
C 
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Figure 13: HmtTrpRS is a dimer in solution with ~100% active sites participating in catalysis. Our 
purification scheme routinely produced catalytically-active HmtTrpRS enzyme with 75-100% of the active 
sites participating in catalysis. The fraction of active sites was determined by active site titration (top; 
TLC plate) using 10 µM ATP, 3 µM total HmtTrpRS active sites (1.5 µM dimer) and 1 mM tryptophan.   
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concentration of total active sites, then we routinely derive a number between 0.75 and 1. This 
demonstrates that both active sites of the HmtTrpRS dimer are capable of participating in the 
tryptophan-activation reaction at comparable rates.  
N-terminal truncations have minimal effect on catalytic efficiency 
Jorgensen et al. (28) described residues 1-19 as the mitochondrial targeting signal, while 
MitoProt (http://ihg.gsf.de/ihg/mitoprot.html) predicted that the localization signal continues 
through residue 33. Michaelis-Menten kinetics for full-length, ∆1-18, and ∆1-33 variants of 
HmtTrpRS showed comparable kcat/KM values (Table 7). As the ∆1-18 variant consistently 
yielded higher protein concentrations and was efficiently cleaved by TEV protease, all kinetic, 
thermodynamic and structural studies were carried out on this variant.  
H
mt
TrpRS k
cat
/K
M
 (s
-1
 M
-1
) (kcat/KM) relative 
1-360 1.35E04 ± 4.57E02 1.00 ± 0.05 
Δ 1-18 1.29E04 ± 7.34E02 0.96  ± 0.06 
Δ 1-33 1.42E04 ± 9.01E02 1.05 ± 0.08 
Table 7: Catalytic efficiency of HmtTrpRS is independent of residues 1-33. Steady-state kinetics 
experiments tracking the incorporation of 32P-PPi into ATP were performed at saturating tryptophan and 
variable ATP concentrations with three variants of the HmtTrpRS enzyme. The data, fitted by non-linear 
regression modeling to simultaneously determine KM ATP and kcat, show that the three variants have 
statistically indistinguishable catalytic efficiencies. 
 
Indolmycin is a tight-binding inhibitor of HmtTrpRS 
Table 8 summarizes our determination of the indolmycin inhibition constant by steady-
state kinetics as well as the dissociation constants obtained by isothermal titration calorimetry. 
The human mitochondrial (Hmt)TrpRS is about 130-fold less proficient than the bacterial 
enzyme, owing to roughly similar differences in both kcat (7-fold smaller) and KM (19-fold 
greater). Despite the extensive structural similarity between indolmycin and substrate tryptophan 
indolmycin selectively binds approximately 1000x tighter to BsTrpRS and HmtTrpRS than the 
 54 
 
 
 
natural tryptophan substrate. Cytosolic isoforms of eukaryotic TrpRS bind tryptophan ~1500x 
tighter than indolmycin. Thus, although both substrate and inhibitor share the indole ring and 
have similar hydrogen bonding groups associated with all three α-carbon substituents, 
indolmycin exploits the apparently minor differences elsewhere to enhance binding to bacterial 
TrpRS, yet reduce binding to the cytosolic TrpRS, leading to a discrimination between the 
cytosolic and bacterial forms of close to 106-fold.  
Parameter Indolmycin [M] Mg
2+
•ATP 
Ki 8.45E-08 ± 1.43E-08  present 
KD 5.46E-08 ± 9.47E-09  present 
KD 4.21E-06 ± 6.22E-07  absent 
Table 8: Indolmycin inhibits HmtTrpRS and its binding is potentiated by Mg2+•ATP. Steady-state 
kinetics experiments performed with saturating amounts of ATP at various tryptophan and indolmycin 
concentrations show indolmycin inhibits HmtTrpRS with nanomolar affinity (row 1). Measuring 
dissociation constants (KD) for indolmycin in the presence (row 2) and absence (row 3) of Mg2+•ATP by 
isothermal titration calorimetry revealed an enhanced affinity of the HmtTrpRS•Mg2+•ATP complex for 
indolmycin over apo-HmtTrpRS. The measured KD in the presence of Mg2+•ATP agrees with the 
experimentally-derived Ki. 
 
From our studies we determined that HmtTrpRS is 42-times less likely to bind indolmycin than is 
BsTrpRS and ~104-times more likely than eukaryotic cytosolic TrpRS enzymes. The reduced 
sensitivity of mitochondrial TrpRS relative to BsTrpRS defines a quantitative window within 
which it may be possible to design useful bacterio-specific anti-infective agents. 
Indolmycin-induced thermal stability is not enhanced by Mg2+•ATP 
 As revealed by differential scanning fluorimetry, apo-HmtTrpRS (ΔTm= 83.7 ± 0.5°C) is 
more stable than apo-BsTrpRS (ΔTm= 69.0 ± 0.2°C) by ~15°C. As we expected ligand binding to 
confer additional thermal stability to HmtTrpRS we modified our assay buffer to include 1 M 
guanidine-hydrochloride, which lowered the melting temperature of apo-HmtTrpRS by ~7°C. 
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Surprisingly, saturating concentrations of neither ATP nor tryptophan have strong effects on the 
thermal stability of HmtTrpRS (Table 9).  Indolmycin was the only ligand tested that altered the 
thermal stability, shifting Tm by ~9°C. In contrast to the results of similar experiments using 
BsTrpRS, the presence of Mg2+•ATP did not alter the stabilizing effect of indolmycin on 
HmtTrpRS (Table 9). 
Ligand Tm (°C) Stdev Tm 
LF 76.69 0.55 
Mg2+•ATP 77.00 0.56 
Trp 77.12 0.66 
TNH 77.28 0.46 
TNH + Mg2+•ATP 77.34 0.44 
IND 85.95 0.89 
IND + Mg2+•ATP 85.51 0.75 
Table 9: Ligand-dependent thermal stability of HmtTrpRS. Neither substrates (ATP or tryptophan) nor 
the substrate analog tryptophanamide contributed to the thermal stability of HmtTrpRS in the transition to 
molten globule formation. Similarly, full occupancy of both the ATP and tryptophan binding sites (with 
either Trp or LTN) did not the enzyme’s thermal stability profile. Indolmycin binding enhanced thermal 
stability by ~9°C. Unlike was observed for BsTrpRS, there was no additional stability conferred by 
having both indolmycin and Mg2+•ATP bound to the active site. 
 
Indolmycin affinity is enhanced by Mg2+•ATP binding 
Isothermal titration calorimetry experiments showed 1:1 binding of indolmycin to each 
active site of the functional HmtTrpRS dimer with a dissociation constant (KD) of 4.2 ±0.6 µM 
(Fig. 14A and Table 8). Pre-loading the enzyme with Mg2+•ATP results in ~77-fold tighter 
binding of indolmycin and a KD of 54.6 ±9.5 nM (Table 8, Fig. 14B). This value correlates well 
with our kinetically-derived Ki of 84.5 ±14.3 nM. Based on our inhibition studies we expected a 
difference of approximately -4 kcal/mol between the Gibbs free energies, ΔΔG, of the fully-
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liganded inhibited (IND + Mg2+•ATP) and catalytic (Trp + Mg2+•ATP) complexes. Titration of 
HmtTrpRS•Mg2+•ATP with indolmycin and tryptophanamide, a non-reactive tryptophan analog 
shown to preserve most, if not all, of the tryptophan-TrpRS interactions, yielded a ΔΔG of -3.1 
kcal/mol (Fig. 15A, B, C).  
Oxazolinone-Mg2+•ATP interaction stabilizes the indolmycin-inhibited complex 
 If we consider tryptophan and indolmycin as both having an indole moiety while 
tryptophan lacks the methylamino-substituted oxazolinone ring (OXA), then we can describe 
tryptophan(amide) as +indole, -OXA and indolmycin as +indole, +OXA (Fig. 15A). Any 
differences in Gibbs free energy between the HmtTrpRS•tryptophanamide, ΔG = -6.80 ± 0.10 
kcal/mol, and HmtTrpRS•indolmycin, ΔG = -7.67 ± 0.11 kcal/mol, complexes are attributed to 
OXA (Fig. 15B). Bearing this in mind we determined that the added OXA moiety provides 0.87 
kcal/mol (ΔΔG2) of stabilization energy upon binding to apo-HmtTrpRS (Fig. 15C).   Given our 
previous result that Mg2+•ATP enhances the affinity of HmtTrpRS for indolmycin with the 
HmtTrpRS•Mg2+•ATP•IND complex being more stable than the HmtTrpRS•IND complex by 2.65 
kcal/mol (ΔΔG3) we wanted to know if Mg2+•ATP has a similar impact on the energetics of 
tryptophan binding. 
Interestingly, the HmtTrpRS•Mg2+•ATP•LTN and HmtTrpRS•LTN complexes only differ 
by 0.46 kcal/mol (ΔΔG1), suggesting that the oxazolinone moiety of indolmycin is critical for the 
Mg2+•ATP-dependent stabilization. These four measurements allowed us to construct a 
thermodynamic cycle in which tryptophanamide, used in lieu of tryptophan to prevent catalysis, 
was the starting point (upper left corner), Mg2+•ATP was varied from top (absent) to bottom 
(present), and OXA was varied from left (absent) to right (present) (Fig. 15C). Subtracting left 
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Figure 14: Pre-binding with Mg2+•ATP enhances the affinity of HmtTrpRS for indolmycin. 
Isothermal titration calorimetry experiments revealed a 1:1 binding stoichiometry of 
indolmycin:HmtTrpRS active site both in the absence (A) and presence (B) of Mg2+•ATP. Apo-HmtTrpRS 
binds indolmycin ~77-times weaker than does Mg2+•ATP-bound HmtTrpRS.  
 
A B 
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from right and top from bottom gives the difference in Gibbs free energy (ΔΔG) due to the 
addition of OXA and Mg2+•ATP, respectively. Non-equivalence of ΔΔG for opposing faces of 
the cycle, resulting from non-additivity of the energetic contributions of OXA and Mg2+•ATP, is 
indicative of an interaction between OXA and Mg2+•ATP in the HmtTrpRS•Mg2+•ATP•IND 
complex. It is evident from this thermodynamic cycle that the effect of adding both OXA and 
Mg2+•ATP is greater than the sum of their individual effects; i.e. the stabilizing effect of one is 
dependent on the presence of the other.  The non-additivity of the energetic contributions of 
Mg2+•ATP and the OXA moiety reveals a ΔΔGinteraction of -2.20 kcal/mol in the 
HmtTrpRS•IND•Mg2+•ATP complex. The difference in Gibbs free energy for this complex and 
HmtTrpRS•LTN is -3.5 kcal/mol or ΔΔG1 +  ΔΔG2 + ΔΔGint (Fig. 15C).  
Indolmycin binds to HmtTrpRS as a ternary complex with ATP 
Unlike the closed-state crystal structures of BsTrpRS, all of which have a monomer in the 
asymmetric unit, HmtTrpRS crystallized in space group C121 with a dimer in the crystallographic 
asymmetric unit and diffracted to 1.82 Å (Fig. 16A and Table 10). Each monomer contains ATP, 
Mn2+ and indolmycin in the active site at essentially full occupancy. Mn2+ was used in 
replacement of Mg2+ because we hoped to use the Mn2+ anomalous signal to derive experimental 
phase information. Although the signal was too weak for phasing, the anomalous signal did 
allow us to definitively identify the metal binding site. There was no electron density in which to 
place N-terminal residues 19-33 and 19-28 in monomers A (grey) and B (purple), respectively.  
Using areaImol (62, 63), monomer A has a solvent-accessible area of 13957.4 and 
15918.3 Å2 in the presence and absence of monomer B, respectively. The solvent-accessible area 
for monomer B alone is 15642.4 Å2 and 13695.5 Å2 in the dimer. The calculated buried surface 
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Figure 15: The potentiation effect of Mg2+•ATP is mediated via the methylamino-substituted 
oxazolinone (OXA) moiety of indolmycin. (A) LTN is a conservative substitute for the tryptophan 
substrate in which the sole difference is replacement of a carboxylate oxygen atom by an amine group. 
Both have an indole moiety and lack the oxazolinone ring present in indolmycin. (B) The relative stability 
of four HmtTrpRS complexes were assessed using thermodynamic measurements obtained from replicate 
ITC experiments. With a difference in Gibbs free energy of 3.5 kcal/mol the LTN and IND•Mg2+•ATP 
complexes are the least and most stable, respectively. (C) The structural differences between LTN and 
IND account for a ΔΔG2= -0.87 kcal/mol. This stabilizing effect more than triples to -3.07 kcal/mol 
(ΔΔG4) in the presence of Mg2+•ATP due to an interaction energy (ΔΔGint) between the methylamino-
substituted oxazolinone moiety and Mg2+•ATP of -2.20 kcal/mol. (0,0) = -OXA, -ATP; (0,1) = +OXA, -
ATP; (1,0) = -OXA, +ATP; (1,1) = +OXA, +ATP; -OXA = tryptophanamide; +OXA = indolmycin. 
A 
B C 
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area due to dimer formation is 3907.8 Å2. Similar calculations using pymol yielded a buried 
surface area of 3815.5 Å2. As is the case for the bacterial enzyme, a prominent feature of the 
dimer interface is the burial of a tryptophan side-chain (Trp 125) across the dimer interface into a 
space bounded by the specificity helix of the other monomer (Fig. 16B). A hydrogen bond 
between the carbonyl oxygen of Leu 76 and NE1 of Trp 125 helps stabilize the dimer interface.  
As measured from CH2, Trp 125 is 4.0 Å away from OG1 of Thr 159 and 4.1 Å from the Cα of 
Tyr 160. Both Thr 159 and Tyr 160 are part of the specificity helix and Tyr 160 stacks against 
the oxazolinone ring of indolmycin.  
Superposition of the two monomers reveals structural differences in the region of loop 
144-150 (Fig. 16C, D) that are presumably responsible, in part, for the inclusion of a dimer in the 
asymmetric unit. This loop is disordered in HmtTrpRS monomer B, as evidenced by a lack of 
electron density, but well-ordered in monomer A. His 140 to Ala 144 of monomer A is helical 
and angled away from the active site compared to the helix formed by His 140-Thr 146 in 
monomer B. Residues from Thr 147 to Asp 152 form a helix in monomer A but cannot be placed 
in monomer B. This region contains a catalytically-relevant lysine residue, Lys 145, which is 
homologous to Lys 111 in BsTrpRS. The relative positions of Lys 145 in the two monomers 
differ by 5.1 Å as measured from the α-carbons following superimposition of monomer B onto 
monomer A (Fig. 16D). The NZ atom of Lys 145 is 9.9 Å away from the nearest gamma 
phosphate oxygen atom in monomer A but only 5.4 Å away in monomer B. While neither 
residue is in position to form direct interactions with ATP as is observed in the BsTrpRS pre-
transition state and inhibited complexes, Lys 145 in monomer B does structurally align with 
BsTrpRS Lys 111. Loop 148-152 corresponds to residues 112-117 in BsTrpRS, which also was 
fitted with difficulty for some structures, depending on which ligands occupied the active site. 
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Kinetic analysis of mutants in this region in both TrpRS (20, 64) and TyrRS (64)  show that 
residues from this loop contribute to ATP binding only in the transition state and imply that 
movement of the loop occurs during catalysis. In BsTrpRS Lys 111 competes with the catalytic 
Mg2+ ion for the same negatively charged gamma phosphate oxygen atom in the pre-transition 
state (2.9 Å) and inhibited state (3.4 Å) complexes. Mutation of Lys 111 to alanine affects kcat 
but not KM for ATP (20).  
The HmtTrpRS anticodon-binding domain is rotated ~5 degrees closer to the Rossmann 
fold domain than it is in the PreTS and inhibited BsTrpRS structures. Without knowing structures 
of tRNA complexes for either protein, it is possible only to speculate that this difference relates to 
differences between the respective tRNA structures. 
Indolmycin interactions with active-site side-chains mimic those observed for BsTrpRS 
The indole moiety of indolmycin is recognized by Asp 167 of the specificity helix as is 
observed for the homologous Asp 132 in BsTrpRS complexes (Fig 17B). Specifically, the side-
chain of Asp 167 accepts a hydrogen bond (3.0 Å) from the pyrrole ring nitrogen. Phe 38 forms 
π-π stacking interactions while Ile 41, Val 74, Ile 168, Val 176 and Val 178 make van der Waals 
contacts with indolmycin. Side-chain atoms of His 77 and Gln 182 donate hydrogen bonds to the 
methylamino nitrogen (3.0 Å) and carbonyl oxygen (3.1 Å) atoms of indolmycin, respectively. 
The carbonyl oxygen accepts an additional hydrogen bond from a metal-coordinating water 
molecule, as does the oxazolinone nitrogen (Figure 17A, B).  
HmtTrpRS binds ATP in an extended conformation 
HmtTrpRS utilizes conserved residues for substrate recognition and binding. As was 
observed for the indolmycin-inhibited BsTrpRS complex, the negative charges of the 
triphosphate oxygen atoms form strong electrostatic interactions with a metal ion. In this 
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                            Data Collection                                                   _                                          
Space group  
Cell Constants 
a, b, c, α, β, γ 
Resolution (Å) 
Completeness (%)a 
Rmerge (%)a 
Rmeas (%)a 
Rpim (%)a 
Mean I/σI a 
Number of Observations 
Multiplicity 
C 1 2 1 
58.289 Å 78.087 Å 153.996 Å 
90.00° 96.55° 90.00° 
29.06 – 1.82 
98.5 (95.8) 
7.7 (59.4) 
9.8 (76.1) 
6.0 (47.0) 
8.1 (1.5) 
139667 
2.3 
                            Refinement                                                         _ 
Rwork/Rfree (%) 
Fo, Fc correlation 
RMS (bonds) 
RMS (angles) 
Ramachandran favored (%) 
Ramachandran outliers (%) 
Average B, all atoms (Å2) 
Clash score 
PDB Entry ID 
17.2/20.7 
0.96 
0.004 
0.92 
97.0 
0.0 
28.8 
5.76 
5EKD 
aHighest resolution shell is shown in parentheses. 
Table 10: Data collection and refinement statistics for HmtTrpRS inhibited complex. The 
HmtTrpRS•Indolmycin•Mn2+•ATP complex was determined to 1.82 Å resolution by molecular 
replacement using the BsTrpRS inhibited complex (PDB 5DK4) as a model. The final structure was 
refined to an RWork/RFree of 17.0/20.7%. 
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Figure 16: Dimeric HmtTrpRS binds one molecule of ATP and indolmycin per active site. (A)Two 
monomers, A (grey) and B (purple), form the functional dimer. (B) A prominent feature of the dimer 
interface is the inter-monomeric burial of Trp 125, whose side chain is stabilized by a hydrogen bond to 
the carbonyl oxygen of Leu 76. This feature was also observed in several BsTrpRS structures. (C) 
Structurally, the two monomers are quite similar but show variation in the position of residues 140-150. 
(D) The importance of this difference to ligand binding is unknown. However, Lys 145 is analogous to 
Lys 111Bs, which shows ligand-dependent structural variation.  
 
 
D 
C 
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case, Mn2+ is hexavalently coordinated by an oxygen atom from each phosphate group and three 
water molecules (Fig. 17A). The three phosphate groups are additionally stabilized by direct and 
water-mediated protein interactions. Gln 42 (2.8-3.0 Å), Asn 51 (3.1 Å) and Lys 229 (2.8 Å) 
form contacts with Pα, while Lys 226 (2.9 Å), Lys 229 (2.9 Å) and His 48 (2.9 Å) donate 
hydrogen bonds to Pβ oxygen atoms (Fig. 17C).The backbone amide and side-chain hydroxyl 
groups of Ser 230 contribute to the stabilization of Pγ via two hydrogen bonds (3.2 and 2.6 Å). 
Thr 44, Lys 145 (B), Ser 228, and Lys 229 form additional water-mediated interactions with 
gamma-phosphate oxygen atoms.  
The adenine 6-amino group donates a hydrogen bond to the backbone carbonyl oxygen 
atoms of Val 217 (2.9 Å) and Met 227 (2.9 Å) (Fig. 17D). The nitrogen atoms of the adenine 
ring accept hydrogen bonds from the amide groups of Val 217 (3.1 Å) and Gly 50 (3.1 Å) as well 
as from the side-chain NZ atom of Lys 226 (3.0 Å). The ribose moiety interacts with the 
conserved HIGH (48-51) and GxDQ (179-182) motifs. Specifically, the 2’OH group accepts a 
hydrogen bond from Gly 179 (3.0 Å) and donates a hydrogen bond to Asp 181 (2.7 Å) while Asn 
51 donates a hydrogen bond to the ringed oxygen atom. The 3’OH group forms a close 
interaction (2.6 Å) with a water molecule (Fig. 17D). These interactions mimic closely those 
observed in BsTrpRS pre-transition state complexes (17, 22, 42). 
Mutations to active site residues have greater impact on kcat than KM ATP 
To confirm the functional equivalences with BsTrpRS inferred from the HmtTrpRS 
structure, we chose to assess the impact of amino acid substitution at positions 42, 48, 145, 181, 
and 229. Gln 42, Asp 181 and Lys 229, which form direct polar interactions with ATP (Fig 17C, 
D) and are conserved at positions 9, 146, and 195, respectively, in BsTrpRS were individually 
mutated to alanine while His 48, which is analogous to BsTrpRS Thr 15, was mutated to  
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Figure 17: Molecular determinants of indolmycin and ATP binding are conserved in HmtTrpRS 
and BsTrpRS. (A) Like BsTrpRS, the inhibited HmtTrpRS complex involves a hexacoordinated-metal 
ion. (B) Binding of indolmycin involves hydrophobic, π-π, and hydrogen bonding interactions. The 
interactions with His 77, Asp 167, Gln 182 and two metal-coordinated water molecules mirror those 
observed in the inhibited BsTrpRS complex. (C) ATP binds in an extended configuration with the HIGH 
and KMSKS motifs stabilizing the triphosphate moiety. (D) The adenine and ribose moieties of ATP are 
recognized by the three signature sequences for class I aaRS enzymes; HIGH, GxDQ and KMSKS.  
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threonine. Although we did not observe direct interactions with ATP, we chose to substitute Lys 
145 with an alanine due in part to the structural variation between monomers A and B as well as 
the 18.5-fold decrease in kcat observed for the corresponding K111A BsTrpRS mutant.  
In all, these amino acid substitutions cause less than a two-fold change in ATP affinity 
but vary greatly in their impact on kcat (Fig.18, Table 11). The H48T variant retained the most 
catalytic activity with a modest 1.4-fold reduction in kcat while substitution of alanine for Lys145 
eliminated ~75% of the enzyme’s catalytic efficiency. By comparison, the K111A BsTrpRS 
variant is 94% less efficient than wild-type BsTrpRS. Alanine substitution of Gln 42, which 
forms a hydrogen bond with each non-bridging alpha-phosphate oxygen atom of ATP, preserves 
the weak backbone interaction (3.4 Å) but eliminates the hydrogen bond formed between the 
side chain amide nitrogen and the metal-coordinated Pα oxygen (3.0 Å). The Q42A mutant has a 
relative catalytic efficiency of 0.15 due primarily to a 9.4-fold reduction in kcat. Alanine 
substitution of either Asp 181 or Lys 229 disrupts the electrostatic environment of the active site 
as well as the hydrogen bonding network between the enzyme and ATP substrate. Removal of 
the negatively-charged Asp 181 results in a 50-fold reduction in kcat. Alanine substitution of Lys 
229 has an even greater effect on catalysis. The catalytic efficiency of the K229A mutant enzyme 
is only 0.5% that of wild-type HmtTrpRS. Thus, as observed both for BsTrpRS (20) and BsTyrRS 
(64), active site interactions with ATP appear to manifest mutational effects only in the transition 
state affinity. 
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HmtTrpRS kcat (s-1) KM (M) kcat/KM (s-1 M-1) 
WT 4.61 ± 0.03 3.59E-04 ± 2.23E-05 1.29E04 ± 7.34E02 
H48T 3.28 ± 0.01 3.95E-04 ± 3.00E-06 8.30E03 ± 5.08E01 
K145A 1.27 ± 0.13 4.38E-04 ± 1.24E-04 3.09E03 ± 1.09E03 
Q42A 0.49 ± 0.01 2.55E-04 ± 2.52E-06 1.92E03 ± 2.05E01 
D181A 0.09 ± 0.01 5.36E-04 ± 9.09E-05 1.60E02 ± 1.49E01 
K229A 0.02 ± 0.01 3.71E-04 ± 7.33E-05 6.35E01 ± 2.37E01 
Table 11: Reduced catalytic efficiency of active site mutants is driven by diminished kcat. Amino acid 
substitutions to residues involved in ATP binding to HmtTrpRS have a broader effect on kcat than KM ATP. 
Alanine substitution at either position 181 or 229 abolished ~99% of the catalytic efficiency while the 
K145A and Q42A variants lost 75% and 85%, respectively. 
 
 
Figure 18: Mutations to active site residues have varying effects on catalytic efficiency. Data from 
steady-state Michaelis-Menten experiments were fitted by non-linear regression modeling to determine 
kcat and KM ATP for six HmtTrpRS variants. The catalytic efficiency of each variant was determined and 
normalized to the wild-type Δ1-18 enzyme. The H48T and K229A mutants were the most and least 
efficient variants, respectively. 
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Discussion 
There are distinctive evolutionary divergences between the eukaryotic and bacterial 
TrpRS enzymes (13, 58).  Curiously, there is low conservation between the cytosolic, 
mitochondrial and bacterial TrpRS homologs at residues shown to form stabilizing interactions 
with tryptophan in HcTrpRS. These sequence and structural variations affect the way these 
enzymes respond structurally following substrate binding, how they couple conformational 
changes to catalysis, the manner in which they hold the tryptophanyl-5’ AMP intermediate as 
well as their ability to discriminate between tryptophan and other indole-containing compounds. 
This latter feature protects eukaryotic cytosolic TrpRS enzymes from inhibition by indolmycin 
while, as will be discussed, leaving mitochondrial and most prokaryotic TrpRS enzymes 
susceptible to inhibition. 
Shared inhibition mechanism of BsTrpRS and HmtTrpRS by indolmycin 
Structural, kinetic and thermodynamic studies of BsTrpRS and HmtTrpRS identify a 
shared mechanism for indolmycin inhibition of prokaryotic and mitochondrial TrpRS enzymes. 
Specifically, a conserved aspartic acid (Asp132BS; Asp167Hmt) in the specificity helix recognizes 
the indole nitrogen while recognition of the methylamino-nitrogen and carbonyl oxygen atoms of 
indolmycin by ND1 of His 77 (His 43BS) and the side chain amide nitrogen of Gln 182 (Gln 
147BS), respectively, restrict the plane of the oxazolinone ring. Indolmycin is further stabilized 
by hydrogen bonding interactions via the carbonyl oxygen and oxazolinone nitrogen atoms with 
two metal-coordinated water molecules. The presence of the catalytic metal ion is required for 
the non-additive interaction energy between indolmycin and ATP. In the presence of Mg2+, the 
oxazolinone-ATP interaction contributes ~-2.2 kcal/mol to the indolmycin binding energy. The 
additional contacts made with the oxazolinone moiety results in BsTrpRS and HmtTrpRS each 
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having a higher affinity for indolmycin than its tryptophan substrate while the 
oxazolinone•Mg2+•ATP interaction locks the enzymes in a stable, off-path inhibited state.  
Conserved aspartic acid recognizes indole nitrogen 
Human mitochondrial TrpRS has an aspartic acid residue in its specificity helix that is 
conserved among prokaryotic but not eukaryotic cytosolic TrpRS enzymes. The side-chain of 
this residue is used by prokaryotic TrpRSs to recognize the indole nitrogen of the tryptophan 
substrate and contributes to binding stability via a hydrogen bond. Eukaryotic cytosolic TrpRS 
enzymes, which lack this aspartic acid residue, rely on a tyrosine and glutamine that are closer to 
the N-terminus for recognition of the indole nitrogen. HcTrpRS, which lacks a homologous 
aspartate in its specificity helix, undergoes induced fit rearrangement of its active site in response 
to tryptophan binding (23, 25, 27). This rearrangement relies on specific hydrogen bonding 
pattern between the tryptophan substrate and active site residues, allowing HcTrpRS to better 
discriminate between tryptophan and other indole-containing compounds. Of the six HcTrpRS 
residues that make direct contacts with tryptophan only one residue beside the strictly conserved 
glutamine of the GxDQ motif is conserved in HmtTrpRS (Fig. 11).  Tryptophan binding to 
BsTrpRS, promoted by a single hydrogen bond between the indole nitrogen of tryptophan and 
Asp 132 of the specificity helix, does not induce structural changes of the active site. 
Susceptibility to indolmycin inhibition, same mode of indole recognition, and high conservation 
of active-site residues imply a shared mechanism for tryptophan activation. 
Role of active-site lysines in ATP binding and catalysis 
The importance of positively charged active site lysine residues in stabilizing the 
negatively charged triphosphate oxygen atoms of ATP has been studied extensively in the case 
of BsTrpRS. Lysines 111 and 192 compete with the catalytic Mg2+ ion for stabilizing the 
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negative charge of the PPi leaving group, while Lys 195 interacts with a non-bridging alpha-
phosphate oxygen as well as the oxygen atom bridging the alpha and beta phosphates. HcTrpRS 
is missing lysines at analogous positions for both 111 and 195, the consequence of which is 
altered ATP configuration (bent instead of extended) and Mg2+•ATP coordination. From the 
fully-liganded inhibited complex it is evident that HmtTrpRS binds ATP in a conformation 
similar to that observed in all ATP-bound BsTrpRS structures with a catalytic metal forming 
electrostatic interactions with oxygen atoms from each phosphate group. Lysine 226 (Lys192BS) 
competes with the metal for the same beta-phosphate oxygen, while Lys 229 (Lys195BS) forms 
electrostatic and hydrogen bonding interactions with an alpha-phosphate oxygen atom. Both of 
these interactions mimic those observed in BsTrpRS. Indolmycin binding to BsTrpRS weakens 
lysine-ATP interactions while strengthening ATP-metal interactions. Part of a highly mobile 
loop, the positioning of Lys 111 varies depending on the ligands bound to the active site. The 
strength of the interaction with gamma-phosphate oxygen is weaker in the presence of 
indolmycin than tryptophanamide (and presumably tryptophan). This residue is conserved in 
HmtTrpRS (Lys 145) but has great structural variation between the two monomers that make up 
the dimer in the crystallographic asymmetric unit. While neither lysine is close enough for direct 
interactions with ATP in the inhibited complex, our kinetic characterization of a K145A mutant 
shows that this residue contributes to the stability of the catalytic transition state as was observed 
for Lys 111 in BsTrpRS (20). Together, these data point to a shared role of active site lysines in 
the binding of ATP as well as the neutralization of negatively charged PPi leaving group 
following tryptophan activation between BsTrpRS and HmtTrpRS. However, the contribution of 
Lys 145 to transition state stabilization of HmtTrpRS is not as great as that of Lys 111 for 
BsTrpRS. The lack of additional structures for HmtTrpRS showing conformational variation 
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prevents us from make conclusions on the possible parallel role of Lys 145 in the catalytic 
mechanism. 
Overall structural agreement between HmtTrpRS and BsTrpRS, but not HcTrpRS 
The inhibited HmtTrpRS structure determined in this work is the only structure to date for 
a mitochondrial TrpRS enzyme. While it does not represent a catalytically-relevant state, it does 
allow us to make structural comparisons with BsTrpRS and HcTrpRS, for which there are 
various structures deposited into the PDB. Superposition of the indolmycin-inhibited BsTrpRS 
and HmtTrpRS structures gives an RMSD of 1.2 Å for 289 Cα-atom pairs. There is excellent 
agreement in the spatial positioning of the ligands within each active site (Fig. 19B). Comparison 
of these active sites, defined as residues within 6 Å of each ligand, revealed even greater 
structural similarity among active residues (0.5 Å RMSD). Similar comparison of the active sites 
of inhibited HmtTrpRS and preTS BsTrpRS yielded an RMSD of 0.5 Å. Although the 
replacement of tryptophanamide with indolmycin in BsTrpRS results in weaker enzyme-ligand 
interactions, global structural changes are minimal. These two structures (preTS and inhibited) 
differ by 0.3 Å over 323 Cα-atom pairs (Fig. 19A).  
As discussed in a previous section, HcTrpRS uses N-terminal residues that are not 
conserved in prokaryotic or mitochondrial TrpRS enzymes to bind tryptophan. Additionally, the 
absence of two lysine residues involved in ATP binding to prokaryotic TrpRS results in 
HcTrpRS binding an altered ATP configuration. Together, these differences result in an HcTrpRS 
active site that greatly differs from that of BsTrpRS (3.0 Å RMSD) and HmtTrpRS (2.6 Å 
RMSD). Superposition of the tryptophanamide indole moieties for the preTS HcTrpRS and 
BsTrpRS structures illustrates the high degree of structural variation in the two active sites (Fig. 
19C). It is immediately clear that, unlike for similar superpositions of HmtTrpRS and BsTrpRS, 
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there is not good agreement in the placement of ligands relative to conserved HIGH and KMSKS 
signature elements; i.e. we cannot reasonably align all elements simultaneously (Fig. 19B, C). 
The greater structural similarity both overall (1.2 Å vs 5.0 Å RMSD) and at the active site (0.5 Å 
vs 2.6 Å RMSD), the utilization of conserved residues for indole recognition and ATP binding, 
and the shared mechanism for inhibition by indolmycin imply that the path to tryptophan 
activation employed by HmtTrpRS better resembles that of BsTrpRS than HcTrpRS. 
Implications for tryptophanyl-5’ AMP formation by HmtTrpRS 
Differences in the relative positioning of the tryptophan and ATP binding sites result in different 
conformers of tryptophanyl-5’ AMP (TYM) occupying the BsTrpRS and HcTrpRS active sites. 
The TYM bound to BsTrpRS is more extended, with the indole moiety CE3 atom being 1.6 Å 
further away from the 3’OH group than in the corresponding TYM of HcTrpRS. Rigid-body 
fitting of TYM from HcTrpRS into the HmtTrpRS active site fitted by aligning its indole ring to 
that of indolmycin has the biggest difference in adenine/ribose placement compared to bound 
ATP (Fig. 20A). This conformer clashes with various residues including Gly 179 and Lys 215. 
When aligned to the adenine moiety of ATP this same conformer loses the interaction between 
Asp 167 and the indole nitrogen (Fig. 20B). Additionally, there are clashes with Gln 42 and Gln 
164. HmtTrpRS should hold onto the indole nitrogen during catalysis for continued assurance that 
the bound substrate is tryptophan. This appears to be the case for both HcTrpRS and BsTrpRS as 
the enzyme-indole hydrogen bonding interactions are preserved in the pre-transition and product 
state structures of both enzymes. Rigid-body fitting of the BsTrpRS TYM product into the 
HmtTrpRS active by superimposing either the indole or adenine rings maintains the Asp 167-
indole nitrogen interaction (Fig. 20C, D). However, superimposition of the TYM indole moiety 
with that of indolmycin results in the loss of many of the observed HmtTrpRS-ATP interactions, 
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Figure 19: Comparison of BsTrpRS, HcTrpRS and HmtTrpRS active sites. A) Minor side-chain 
rearrangements and a shift in metal position (green spheres) accompany the replacement of 
tryptophanamide (LTN) in the preTS BsTrpRS structure (grey cartoon and sticks) for indolmycin (yellow 
cartoon and sticks). B) The active sites of HmtTrpRS (purple cartoon and sticks) and BsTrpRS show great 
structural similarity in Cα atoms (0.5 Å RMSD), as conserved elements and bound ligands align well. C) 
The relative positions of LTN, ATP and Mg2+ in the HcTrpRS active site (cyan cartoon, sticks and sphere) 
differs from that observed in BsTrpRS (grey).   
C 
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including those with Asn 51 and Gln 42. Superimposition of the BsTrpRS TYM adenine moiety 
onto that of ATP maintains the Asp 167-indole interaction in addition to all but one of the 
HmtTrpRS-AMP interactions observed in the inhibited complex without introducing steric 
clashes. This analysis suggests that HmtTrpRS is likely to go from a preTS to product state via a 
transition mimicking that of BsTrpRS, with the TYM product adopting the more extended 
conformation observed in the BsTrpRS active site. 
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Figure 20: Rigid body modeling of TYM into HmtTrpRS active site. The TYM (yellow sticks) product 
from HcTrpRS (2QUJ) was modeled into the HmtTrpRS active by superposition of indole (A) or adenine 
(B) moieties. Residues making hydrogen bonding contacts with TYM are shown in cyan while those that 
would clash are shown in grey. The more extended TYM conformer observed in BsTrpRS was similarly 
modeled (C, D). In all panels, Asp 167 is depicted in purple along with the distance to the NE1 atom and 
the original ATP/IND ligands are shown in the background. 
Conclusion 
 
In this work, we established conditions for heterologous expression of soluble, 
catalytically-active HmtTrpRS in E. coli by co-expression with GroEL/ES chaperones. Our 
purification protocol routinely results in homogeneous samples in which 75 to 100% of the 
HmtTrpRS molecules are competent for catalysis. We confirmed our hypothesis that conserved 
C 
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elements, including Asp 167 and His 77, leave HmtTrpRS vulnerable to inhibition by indolmycin. 
The 10-8 M inhibition constant is an order of magnitude weaker than that measured for BsTrpRS, 
consistent with KM tryptophan values for the two enzymes. The 1.82 Å structure and the 
associated thermodynamic studies obtained by isothermal titration calorimetry validated our 
interpretation of the mechanism by which indolmycin inhibits BsTrpRS, specifically by 
simultaneously weakening enzyme-ATP and strengthening metal-ATP interactions to prevent 
metal activation. The structural data suggests that indolmycin binding should be tighter in the 
presence of Mg2+•ATP. Isothermal titration calorimetry experiments validated this claim as pre-
binding Mg2+•ATP enhanced indolmycin binding to HmtTrpRS ~80-fold. Interestingly, this 
potentiation effect could not be observed by differential scanning fluorimetry, where only 
indolmycin altered the thermal stability of HmtTrpRS. The shift by ~9°C in the thermal transition 
to molten globule formation induced by indolmycin binding was independent of Mg2+•ATP. 
Finally, this sole structure of HmtTrpRS allowed us to determine that it employs conserved 
residues and structural elements to recognize the NE1 indole atom and to bind ATP in an 
extended conformation. Both of these features result in an active site arrangement mimetic of 
BsTrpRS but that varies substantially from that of HcTrpRS. Together, work presented in this 
chapter imply a shared mechanism for tryptophan activation between HmtTrpRS and BsTrpRS.  
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CHAPTER IV: CONCLUDING REMARKS AND FUTURE DIRECTIONS 
 
Aminoacyl-tRNA synthetases are essential for accurate protein biosynthesis and the 
fidelity of the genetic code in all organisms. Divergent structural and mechanistic elements in 
aaRS enzymes across the three kingdoms of life make members of this enzyme superfamily 
attractive targets for novel anti-infective therapeutics. We were specifically interested in how the 
natural tryptophan analog indolmycin is able to exploit differences between prokaryotic and 
eukaryotic TrpRS enzymes such that it preferentially binds prokaryotic TrpRS 106-times more 
readily than eukaryotic homologs. The presented research  i)  provides a mechanistic basis for 
indolmycin inhibition; ii) accounts for the 103-fold tighter affinity that prokaryotic TrpRSs have 
for indolmycin over substrate tryptophan; iii) identifies the structural consequences of 
indolmycin binding; iv) accounts for the ability of eukaryotic cytosolic TrpRSs to evade 
inhibition by indolmycin; and v) establishes mitochondrial TrpRS enzymes as targets for 
inhibition by indolmycin via a shared mechanism with prokaryotic TrpRS. Ultimately, we hope 
this work will lay the foundation for rational design of novel anti-infective agents that exploit 
structural and mechanistic differences among cytosolic, mitochondrial and prokaryotic TrpRS 
enzymes such that these new compounds are maximally selective for prokaryotic TrpRS.  
In Chapter II we uncovered the structural basis for the tight-binding inhibition of 
prokaryotic over eukaryotic cytosolic TrpRS enzymes by indolmycin as well as the 103-fold 
higher affinity for indolmycin over tryptophan observed for many prokaryotic TrpRS enzymes. 
Analysis of the structural rearrangements accompanying ligand binding to BsTrpRS allowed us 
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to identify subtle changes, including altered Mg2+ placement and coordination, which account for 
high-affinity inhibition by indolmycin. In order to experimentally confirm the role of metal 
“locking” in tight-binding indolmycin inhibition we propose conducting ITC experiments in 
which BsTrpRS pre-bound to either tryptophanamide or indolmycin is titrated with Mg2+•ATP. 
As movement of the Mg2+ ion to assist in catalysis weakens the affinity of BsTrpRS for ATP in 
the transition state (V. Weinreb, unpublished result), if indolmycin prevents Mg2+ ion movement 
then we should not see weakened, but rather heightened ATP affinity in the presence of 
indolmycin compared to tryptophanamide.  
DSF experiments confirmed the importance of Mg2+ in mediating stabilizing interactions 
between the oxazolinone moiety of indolmycin and ATP. While Mn2+ substitution for Mg2+ 
alters the kinetics of tryptophan activation, we did not examine the effects of this substitution on 
inhibition kinetics. Preliminary DSF experiments suggest that Mn2+ contributes comparably to 
Mg2+ in promoting the oxazolinone-ATP interaction; i.e. the presence of a divalent cation is 
more critical than the identity (Mn2+ vs Mg2+). In addition to native enzyme, similar metal 
substitution experiments will be conducted using BsTrpRS variants bearing mutations to residues 
involved in long-range coupling to the catalytic metal ion. As discussed in Chapter II these 
BsTrpRS D1 switch variants showed altered ratios for tryptophan versus indolmycin selectivity. 
While extensive studies have been performed by the Carter group to uncover the kinetic and 
thermodynamic contributions of these residues, little has been done to study the structural effects 
of the D1 switch mutations. We have worked out the crystallization conditions for the ternary 
complexes with indolmycin and Mg (or Mn)2+•ATP and collected datasets for a subset of the 15 
combinatorial mutants. Structure determination and analysis is ongoing. 
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The robust stabilizing effect of indolmycin binding is considerably greater than that 
provided upon binding either tryptophan or ATP. While tryptophan alone is not enough to induce 
structural changes, high concentrations of ATP as well as simultaneous binding by ATP and 
tryptophan(amide)  elicit induced-fit closing of the active site to form a pre-transition state. 
Indolmycin binding alone produces a structure that is more stable by 10°C than the closed preTS 
complex with tryptophanamide plus Mg2+•ATP. This result suggests that indolmycin may 
promote global structural changes in the absence of ATP. In order to address this we are working 
to crystallize and determine the structure of BsTrpRS bound by indolmycin alone.  
In Chapter III we determined that mitochondrial TrpRS enzymes are indeed susceptible 
to inhibition by indolmycin. Additionally, high-affinity binding is dependent on Mg2+•ATP. 
Surprisingly, the potentiation of indolmycin binding by Mg2+•ATP was not detected by DSF. In 
fact, we were unable to detect changes in the thermal stability of HmtTrpRS in response to 
binding of any ligand other than indolmycin. While the thermodynamic cycle revealed a 
stabilizing interaction between the oxazolinone moiety and Mg2+•ATP, we do not have 
experimental data showing the dependence of this interaction on the metal ion for HmtTrpRS. 
This requires additional isothermal titration experiments in which we determine the dissociation 
constant for both indolmycin and tryptophanamide in the presence of bound ATP (metal free).  
Despite differences in binding determinants and structural consequences of tryptophan 
binding, both BsTrpRS and HcTrpRS bind tryptophan with comparable binding affinities of ~2 
uM. In contrast, HmtTrpRS, which has a high degree of similarity between active site residues 
with BsTrpRS, binds both tryptophan and indolmycin about an order of magnitude more weakly 
than does BsTrpRS. Examination of the tryptophan-binding pocket for the three enzymes did not 
identify any obvious reason for the weaker binding to HmtTrpRS. Residues in this area are highly 
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conserved between BsTrpRS and HmtTrpRS, as they use the same determinants for tryptophan 
recognition. The only difference we found that may account for the observed differential binding 
affinities is the replacement of a methionine in the specificity helix for a glutamine in HmtTrpRS. 
In BsTrpRS the methionine sulfur atom is in position to interact with the aromatic ring of 
substrate tryptophan. To test if sulfur-aromatic interactions contribute to tryptophan binding I 
propose making and characterizing the tryptophan-binding behavior of M129Q BsTrpRS and 
Q164M HmtTrpRS variants. If sulfur-aromatic interactions promote tryptophan binding I would 
expect the BsTrpRS mutant to have reduced affinity while the HmtTrpRS mutant has increased 
affinity for tryptophan.  
Shared characteristics between HmtTrpRS and BsTrpRS include a mimicked ATP binding 
conformation as well as ATP-metal coordination. Additionally, there is a distinct lack of metal- 
HmtTrpRS interactions which raises questions about metal-enzyme coupling. Specifically, is the 
catalytic metal coupled to a site remote from the HmtTrpRS active site as has been demonstrated 
for the BsTrpRS enzyme? The D1 switch identified in BsTrpRS consists of Ile 4, Phe 26, Tyr 33, 
and Phe 37. Re-packing of these side-chains is coupled to movement of the metal into a 
catalytically-competent position and D1-Mg2+ coupling accounts for the increased tryptophan 
specificity over tyrosine of BsTrpRS primarily through effects on kcat (21, 65). Structure-based 
sequence alignment of the inhibited BsTrpRS and HmtTrpRS structures identify the analogous 
HmtTrpRS residues as Val 37, Trp 59, Tyr 66, and Tyr 71. Additional structures along the 
catalytic path are needed to identify side-chain rearrangements (re-packing) that occur as a 
consequence of substrate binding and catalysis in HmtTrpRS. To that end, we are continuing our 
efforts to obtain X-ray crystal structures of HmtTrpRS along its catalytic path. 
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 Finally, although indolmycin targets HmtTrpRS it does so ~40-times weaker than 
BsTrpRS. This selectivity ratio is higher than many commonly used therapeutics. The fact that 
there is a difference suggests that it may be possible to design novel compounds with increased 
selectivity for prokaryotic over mitochondrial TrpRS enzymes. In silico screening of a virtual 
compound library may identify such compounds, which can then be tested for inhibition of 
HcTrpRS, HmtTrpRS and BsTrpRS. 
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